Coagulation factur V deficiency:from molecular diagnosis to molecular therapy by Nuzzo, F.
  
 
Coagulation factur V deficiency
Citation for published version (APA):
Nuzzo, F. (2016). Coagulation factur V deficiency: from molecular diagnosis to molecular therapy. 's-
Hertogenbosch: Uitgeverij BOXPress.
Document status and date:
Published: 01/01/2016
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
  
Coagulation factor V deficiency: 
From molecular diagnosis to molecular therapy 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
© Francesca Nuzzo,  Maastricht 2016 
Thesis Maastricht University 
No part of this book may be reproduced, stored in a retrieval system or transmitted in any 
form or by any means without prior written permission by the author, or when appropriate, 
by the publishers of the publications. 
 
 
ISBN: 9789462954199 
 
Cover pictures: Ex-vivo differentiated human megakaryocytes (courtesy of Dr. C. Radu). 
Cover design and layout:  Daco Grafica & Design 
Printed by : Proefschriftmaken.nl || Uitgeverij BOXPress 
 
 
 
 
 
 
 
Coagulation factor V deficiency: 
From molecular diagnosis to molecular therapy 
 
 
PROEFSCHRIFT 
 
ter verkrijging van de graad van doctor aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus Prof. Dr. L. L. G. Soete, 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen 
op  
 
 
donderdag, 14 januari 2016 om 16.00 uur 
 
 
door 
 
 
Francesca Nuzzo 
 
Promotor 
Prof. Dr. T. M. Hackeng 
 
Co-promotor 
Dr. E. Castoldi 
 
 
Assessment committee 
Prof. Dr. H. A. J. Struijker-Boudier (chairman) 
Prof. Dr. M. Stoll 
Prof. Dr. P. H. Reitsma (Leiden University) 
Prof. Dr. F. Bernardi (Ferrara University, Italy) 
 
 
 
This PhD project was made possible by a grant from the Cardiovascular Research Institute 
Maastricht (CARIM) and by VIDI grant nr. 917-76-312 from the Netherlands Organisation 
for Scientific Research (NWO). 
Financial support by the Dutch Heart Foundation for the publication of this thesis is 
gratefully acknowledged. 
Financial contribution of Stichting Hartsvrienden Rescar te Maastricht is gratefully 
acknowledged. 
Additional financial support for the publication of this thesis by MRC-Holland is gratefully 
acknowledged. 
 
 
 
                                                                                           “ Tell me and I forget, 
                                                                                              Teach me and I may remember, 
                                                                                               Involve me and I learn.” 
                                                                                               (Benjamin Franklin)
 
 
 
 
Table of contents 
 
  Page 
Chapter 1 General Introduction 1 
Chapter 2 Pre-mRNA splicing as a target for personalized molecular therapy 25 
Chapter 3 Identification of a novel large deletion in a patient with severe 
factor V deficiency using an in-house F5 MLPA assay 
45 
Chapter 4 Novel F5 splicing mutation in a factor V-deficient patient with 
multiple intracranial haemorrhages 
63 
Chapter 5 Characterisation of an apparently synonymous F5 mutation causing 
aberrant splicing and factor V deficiency 
73 
Chapter 6 Antisense-based RNA therapy of factor V deficiency: in vitro and 
ex vivo rescue of a F5 deep-intronic splicing mutation 
95 
Chapter 7 Plasma tissue factor pathway inhibitor modulates bleeding tendency 
in severe factor V deficiency 
121 
Chapter 8 General Discussion 137 
 Summary / Nederlandse samenvatting 165 
 Valorisation 173 
 Curriculum vitae / List of publications 177 
 Acknowledgements 183 
   
 
 
1 
General Introduction 
 
 
 
 
Chapter 1 
 2 
Haemostasis 
Hemostasis1 is a physiological mechanism by which our body maintains the fluidity of the 
blood, heals injured blood vessels and removes blood clots after vascular integrity has been 
reinstated. Disturbances of hemostasis, due to genetic and/or acquired factors, can lead to 
thrombotic or bleeding disorders. 
Hemostasis is the result of the coordinated action of the vessel wall, platelets and several 
plasma proteins (coagulation and fibrinolytic factors). The processes most relevant to the 
work described in this thesis are primary hemostasis, in which platelets adhere to the 
damaged vessel wall and aggregate to form a temporary plug, and especially secondary 
hemostasis, in which the coagulation cascade produces a fibrin network that stabilizes the 
platelet plug. Platelet activation and coagulation reactions overlap in time and space and are 
strongly inter-dependent. 
 
Primary hemostasis 
Platelets 
Platelets2 are 2-4-μm anucleated discoid cells produced in the bone marrow and released in 
the bloodstream, where they circulate at a concentration of 150-400·109/L with a half-life of 
5-10 days. Platelets are characterized by different types of granules: α-granules store several 
proteins, including the coagulation-related proteins fibrinogen, von Willebrand factor (vWF), 
factor V, factor XIII and protein S, whereas dense bodies contain serotonin, ADP, GTP and 
divalent cations (i.e. Ca2+ and Mg2+). Platelets also present a wide variety of membrane 
receptors for (among others) collagen, vWF, fibrinogen, thrombin, ADP and tromboxane A2. 
These receptors mediate the interactions and initiate the signalling pathways that lead to 
platelet adhesion, aggregation and degranulation at the site of injury (see below). 
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Platelets originate in the bone marrow from megakaryocytes, large polyploid cells derived 
from the pluripotent hematopoietic stem cell.3-5 Megakaryocyte differentiation is mainly 
driven by thrombopoietin (TPO) in conjunction with interleukin (IL)-3, IL-6 and IL-11. 
During this process, immature megakaryocytes undergo multiple rounds of endomitosis 
(DNA replication without cytoplasmic division), accompanied by cytoplasmic enlargement 
and a maturation process where secretory granules are formed and the plasma membrane 
invaginates to build an interconnected membrane network of cisternae and tubules 
(demarcation membrane system) within the cytoplasm. Platelets are eventually shed from 
pseudopodia (pro-platelets) extending from this membranous grid. 
 
Platelet adhesion, activation and aggregation 
The role of platelets in primary haemostasis has been recently reviewed.6,7 Upon vessel wall 
injury, platelets interact with components of the exposed sub-endothelial extracellular matrix 
via specific receptors present on their plasma membranes. Initial binding to vWF through the 
glycoprotein (GP)Ib-V-IX receptor and integrin αIIbβ3 causes the platelets to tether and roll 
over the injured endothelium. This is followed by firm adhesion to sub-endothelial collagen, 
which is mainly mediated by the GPVI receptor. Bound platelets undergo a shape change, 
secrete the contents of their granules and expose negatively charged phospholipids 
(phosphatidylserine), providing an ideal surface for coagulation reactions. Thromboxane A2 
(produced by activated platelets), ADP (released from the dense bodies) and thrombin 
(generated by the coagulation cascade) activate additional platelets, recruiting them to the 
growing thrombus. This leads to the formation of a platelet aggregate in which platelets are 
cross-linked by fibrinogen molecules (derived from plasma and platelet α-granules) via 
integrin αIIbβ3. This temporary platelet plug rapidly seals the blood leakage. 
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Secondary hemostasis 
Coagulation factors 
Coagulation factors (each indicated by an “F” followed by a roman numeral) comprise a 
group of proteins mainly synthesized in the liver and circulating in plasma as inactive 
precursors.8  FII (prothrombin) and FVII, FIX, FX, FXI and FXII are zymogens of serine-
proteases, FXIII is a pro-transglutaminase, FV and FVIII are non-enzymatic pro-cofactors 
and fibrinogen is the precursor of fibrin. 
FII, FVII, FIX and FX have an N-terminal domain rich in γ-carboxyglutamate (Gla) residues 
(Gla domain), which mediates Ca2+-dependent binding to negatively charged phospholipids. 
The enzyme responsible for the post-translational γ-carboxylation of glutamate residues in 
the Gla domain requires vitamin K hydroquinone (KH2) as a cofactor, making these proteins 
vitamin K-dependent.9 Un(der)carboxylated coagulation factors are poorly secreted as well 
as non-functional. This forms the basis for anticoagulant therapy with vitamin K antagonists, 
such as warfarin and coumarin, which block vitamin K recycling from the oxidized to the 
reduced (active) state. 
 
Coagulation cascade 
The coagulation cascade10,11 is the process by which coagulation factors are sequentially 
activated, eventually leading to the conversion of fibrinogen to fibrin.12  Most coagulation 
reactions take place at the surface of negatively charged phospholipids13 and some enzymes 
assemble with their cofactors in membrane-bound macromolecular complexes, such as the 
intrinsic tenase complex (FIXa-FVIIIa, which activates FX) and the prothrombinase 
complex (FXa-FVa, which generates thrombin, the most important coagulation enzyme). 
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Since each factor can activate several molecules of the following factor in the cascade, the 
procoagulant signal is considerably amplified along the cascade. 
The classical coagulation model14 comprises two pathways dovetailing in a common 
pathway at the level of the prothrombinase complex (Figure 1). The extrinsic pathway is 
initiated by tissue factor (TF), whereas the intrinsic pathway starts with the activation of 
FXII by “foreign surfaces”, like silica, denatured proteins and RNA. This dual model is still 
reflected in the clotting tests used to diagnose coagulation defects in the clinical laboratory: 
the prothrombin time (PT) probes the extrinsic pathway, while the activated partial 
thromboplastin time (APTT) probes the intrinsic pathway.  
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Figure 1. Coagulation cascade and its regulation. 
The scheme illustrates the intrinsic pathway (brown) and extrinsic pathway (grey) of coagulation, 
converging on the common pathway (green) at the level of FXa. Coagulation factors are indicated in 
red (inactive precursors) and purple (activated enzymes and cofactors). Coagulation inhibitors are 
shown in black. PL, phospholipids. 
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According to the more recent cell-based model of coagulation,14,15 coagulation is initiated by 
TF at the surface of TF-bearing cells. Binding of TF to circulating FVIIa activates small 
amounts of FIX and FX. In turn, FIXa and FXa associate with their respective cofactors 
FVIIIa and FVa (activated by FXa) on the surface of activated platelets to form the tenase 
and prothrombinase complexes, generating trace amounts of thrombin (initiation phase). The 
latter are insufficient to generate fibrin, but enough to amplify the coagulation signal via 
feedback activation of platelets (via protease-activated receptors PAR-1 and PAR-4), FXI 
and the procofactors FV and FVIII (propagation phase). This leads to a tremendous burst of 
thrombin, which cleaves off fibrinopeptides A and B from fibrinogen molecules, giving rise 
to fibrin monomers. The latter spontaneously polymerize to form fibrin fibers, which are 
eventually cross-linked by FXIIIa (activated by thrombin) to form the fibrin network that 
stabilizes the clot (stabilization phase). 
 
Regulation of coagulation 
Several inhibitors acting at all levels of the coagulation cascade limit coagulation reactions 
to the site of injury (Figure 1). 
Tissue factor pathway inhibitor (TFPI)16 is a kunitz-type protease inhibitor mainly 
synthesized by endothelial cells. The human TFPI gene produces two main splicing 
isoforms: TFPIα (containing an acidic N-terminus, three kunitz domains and a basic C-
terminus) and TFPIβ (in which the last kunitz domain and the basic C-terminus are replaced 
by a GPI anchor). Both isoforms are associated with the endothelial surface, but TFPIα is 
also present in platelets and in plasma (plasma concentration ~2.5 nM). However, most 
plasma TFPIα is C-terminally truncated and bound to lipoproteins, only 10% (0.25 nM) 
being in the fully active free full-length conformation. TFPIα and TFPIβ down-regulate the 
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initiation of coagulation by inhibiting both the TF/FVIIa complex (via their kunitz-1 domain) 
and FXa (via their kunitz-2 domain).17 The anticoagulant activity of full-length TFPIα is 
stimulated by its cofactor protein S,18 which binds to the kunitz-3 domain and helps localize 
TFPIα to the membrane surface.19 Moreover, the C-terminus of TFPIα contains a binding 
site for FV,20 which has been proposed to mediate inhibition of prothrombinase by TFPIα.21 
Protein C22,23 is a vitamin K-dependent zymogen produced in the liver and circulating in 
plasma at a concentration of ~65 nM. Protein C is activated by thrombin bound to the 
endothelial transmembrane protein thrombomodulin, a reaction which is enhanced by the 
endothelial protein C receptor. Activated protein C (APC) proteolytically inactivates the 
FVIIIa and FVa, the essential cofactors of the intrinsic tenase and prothrombinase 
complexes, respectively. Both inactivation reactions are greatly stimulated by protein S,23,24 
another vitamin K-dependent protein which acts as a cofactor of APC. Optimal inactivation 
of FVIIIa also requires APC-cleaved FV as an additional APC cofactor. The physiological 
importance of the protein C pathway is underscored by the increased risk of venous 
thrombosis associated with hereditary deficiencies of protein C and protein S.25 
Antithrombin26 is a liver-derived anticoagulant protein belonging to the serpin family. It 
inhibits several coagulation serine proteases, including FIXa, FXa, FXIa, FXIIa and 
thrombin. The efficiency of the inhibition is greatly increased by heparin, mimicked in vivo 
by endhotelial glycosaminoglycans. Antithrombin deficiency is a strong risk factor for 
venous thrombosis.25 
 
Coagulation factor V 
Coagulation factor V (FV),27 also known as proaccelerin or labile factor, was discovery by 
the Norwegian physician Paul Owren in 1947.28 It is mainly synthesized in the liver and 
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circulates in plasma as a 330-kDa single-chain glycoprotein, with a concentration of 20-25 
nM and a half-life of ~13 hours.29 Some FV (~20%) is stored in platelet α-granules,30 where 
it is bound to the soluble protein multimerin-1.31 Although megakaryocytes are able to 
synthesize FV,32  it has been shown that the platelet FV pool derives from endocytosis of 
plasma FV by bone-marrow megakaryocytes.33,34 During its transport to the α-granules, the 
internalized FV undergoes an extensive intracellular processing that makes platelet FV 
structurally and functionally different from plasma FV.35,36 
 
Structure and functions of FV(a) 
Human FV is encoded by the F5 gene, which is localized on the long arm of chromosome 1 
(1q21-25).37 The gene spans ~80 kb and consists of 25 exons and 24 introns.38 Its 7-kb 
mRNA39 encodes a mature protein of 2196 amino acids, organized in six domains (A1-A2-
B-A3-C1-C2). The A and C domains are highly homologous to the corresponding domains 
of FVIII,40 whereas the extremely large B domain has a unique sequence. In particular, this 
domain contains a basic region (residues 963-1008*) and an acidic region (residues 1493-
1537) which engage in a high-affinity interaction that maintains FV in its inactive 
conformation.41 
The “life cycle” of FV is illustrated in Figure 2. FV is activated by thrombin or FXa via 
limited proteolysis at Arg709, Arg1018 and Arg1545.42 These cleavages remove the B-
domain and release activated FV (FVa), which consists of a ~105 kDa heavy chain (A1-A2) 
and a ~72 kDa light chain (A3-C1-C2) non-covalently linked via a calcium ion. FVa binds to 
the serine-protease FXa on the surface of negatively charged phospholipids to form the 
prothrombinase complex, which converts prothrombin to thrombin. As a non-enzymatic 
*Note: All F5 nucleotides and FV amino acids in this Introduction are numbered according to the classical 
nomenclature (based on Jenny et al. 1987),39 which is still the most widely used within the FV community. 
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cofactor of FXa, FVa accelerates prothrombin activation by several orders of magnitude.43 
This property makes it essential for efficient thrombin formation and thus indispensable to 
life. 
A1 A2 A3 C1 C2B
A1 A2 A3 C1 C2
A3 C1 C2
FV
APC/protein S
Thrombin or FXa
Ca2+
Ca2+
FVa
FVi
R306 R506 R679
R709 R1018 R1545
Heavy chain Light chain
Carrier of TFPIα in the circulation
APC-cofactor in FVIIIa inactivation
FXa-cofactor in prothrombin activation
R506
A2 A3 C1 C2BFVac
APC/(protein S?)
A1 A2
A2
A2
A1
Inactive
 
Figure 2. Structure and functions of FV(a). 
Native single-chain FV is boxed. FV can be cleaved by APC to yield an anticoagulant cofactor of 
APC (FVac, top), or by thrombin or FXa to give a procoagulant cofactor of FXa (FVa, bottom). FVa 
is eventually inactivated (FVi) by APC/protein S. APC-cleavage sites are shown in red, thrombin- 
and FXa-cleavage sites are shown in green. 
 
FVa is inactivated by the APC-mediated proteolysis of the heavy chain at Arg306, Arg506 
and Arg679.44,45 Cleavage at Arg506 is kinetically preferred and usually occurs first, but 
cleavage at Arg306 is required for complete FVa inactivation. Cleavage at Arg679 
contributes little to FVa inactivation. The APC-cofactor protein S accelerates FVa 
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inactivation by stimulating cleavage at Arg306.46 When FVa is incorporated in the 
prothrombinase complex, it is protected from APC-mediated inactivation by its interactions 
with FXa and prothrombin.46,47 
In contrast to plasma FV, platelet FV is stored as a partially activated molecule. Following 
platelet activation, it is released from the α-granules, exposed on the platelet surface and 
fully activated by FXa (preferably) or thrombin.48 Platelet FVa is partially resistant to 
inactivation by APC.49 
While FVa is strongly procoagulant, its precursor FV has anticoagulant activity as an 
additional cofactor of the APC/protein S complex in the inactivation of FVIIIa.50-52 
Expression of this APC-cofactor activity requires FV to be cleaved by APC at Arg50653 and 
to be intact at the Arg1545 thrombin-cleavage site.54 
FV also acts as a carrier of TFPIα in plasma,20,55 protecting this anticoagulant protein from 
truncation and/or clearance. In fact, >50% of circulating TFPIα is bound to FV via an 
interaction between the basic C-terminus of TFPIα and the acidic region in the B domain of 
FV.56 Recently, FV splicing variants (FV-short) with increased affinity for plasma TFPIα 
have been described (see below). 
 
Role of FV(a) as regulator of the haemostatic balance 
The numerous pro- and anticoagulant functions of FV(a) make it a pivotal regulator of the 
haemostatic balance. Not surprisingly, mutations in the F5 gene can result in a thrombotic or 
haemorrhagic phenotype.27,57 In particular, the common Arg506Gln mutation (FV Leiden),58 
which abolishes one of the APC-cleavage sites on FV(a), is associated with APC resistance 
and an increased risk of venous thrombosis.59,60 In contrast, mutations that impair the 
synthesis and/or function of FV(a) lead to bleeding manifestations.61 
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FV deficiency 
FV deficiency states can originate from genetic or acquired conditions. Inherited FV 
deficiencies include classical FV deficiency (linked to the F5 gene),61 combined deficiency 
of FV and FVIII (linked to the LMAN1 and MCFD2 genes)62 and the Québec platelet 
disorder (linked to the PLAU gene),63 whereas acquired FV deficiency is most often due to 
the development of anti-FV antibodies (FV inhibitors).64,65 Virtually all FV deficiency states 
are associated with a bleeding diathesis, whose severity depends on the reduction in FV 
levels and to whether or not the platelet FV pool is also affected. 
This thesis focusses on classical FV deficiency66-68 (also known as Owren parahemophilia, 
OMIM +227400), which is a rare bleeding disorder with an incidence of 1 in 1 million and 
an autosomal recessive pattern of inheritance. Patients present with prolonged PT and APTT, 
but the diagnosis must be confirmed with specific assays for FV antigen and activity. 
Like other coagulation disorders, FV deficiency comes in two types: type 1 is a quantitative 
defect characterized by proportionally decreased levels of FV antigen and activity, whereas 
type 2 is a qualitative defect with a normal or sub-normal antigen level, but reduced activity. 
Type 2 FV deficiency is extremely rare and only two cases have been described so far.69,70 
Based on (plasma) FV activity levels, FV deficiency is classified as severe (FV:C <1%), 
moderate (FV:C 1-5%) and mild (FV:C 5-30%), although the correlation between FV levels 
and clinical phenotype is not clearcut. The most common symptoms are easy bruising, 
epistaxis, mucosal bleeding and menorrhagia in females.71,72 Approximately one quarter of 
patients also experience joint and muscle bleeds, whereas life-threatening intracranial and 
gastro-intestinal haemorrhages are rare and confined to the most severe cases. Patients with 
partial FV deficiency (FV:C ~50%) are usually asymptomatic. 
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Since no FV concentrate or recombinant FV preparation is available, the management of 
bleeding episodes in FV-deficient patients still relies on fresh frozen plasma and platelet 
concentrates.73 While most patients respond well to this therapy, repeated plasma 
transfusions may lead to several complications, including volume overload, the transmission 
of infectious agents, immune reactions and transfusion-related acute lung injury (TRALI). In 
contrast to haemophilia A, where substitutive therapy with FVIII often triggers the 
development of inhibitory antibodies, FV inhibitor development in FV-deficient patients 
treated with fresh frozen plasma is a rare occurrence. 
 
Modulators of the bleeding tendency in FV deficiency 
Experiments in mice models have indicated that the complete absence of FV is not 
compatible with life,74 but minimal FV expression is sufficient to rescue the perinatal 
lethality of FV knock-out mice.75 The same applies to humans, where many patients with 
apparently undetectable FV levels experience only moderate bleeding symptoms. This 
observation suggests the existence of compensatory mechanisms which ameliorate the 
clinical phenotype of FV-deficient patients.68 Previous studies from our laboratory have 
identified platelet FV76 and plasma TFPIα levels55  as candidate modulators of the bleeding 
tendency in severe FV deficiency. In particular, we have shown that patients with 
undetectable plasma FV often have traces of residual platelet FV which can support enough 
thrombin generation to prevent fatal hemorrhages.76 Furthermore, we have observed that, due 
to the interaction between FV and TFPIα in plasma, FV-deficient patients have low TFPIα 
levels (~20-30% of normal), which considerably reduces the FV requirement for minimal 
hemostasis.55 Therefore, low TFPIα levels are beneficial to FV-deficient patients and 
variations in TFPIα levels could modulate the bleeding tendency in patients with equally low 
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FV levels. A third, as yet uncharacterized, compensatory mechanism acting on the intrinsic 
coagulation pathway has also been reported in an 83-year-old FV-deficient patient (FV:C 
<2%) with no spontaneous bleeding.77 
 
Genetics of FV deficiency 
FV deficiency is caused by loss-of-function mutations in the F5 gene.61,78 Currently, 153 F5 
mutations are listed in the Human Genome Mutation Database (accessed in March 2015), 
most of which are associated with FV deficiency. The vast majority are missense/nonsense 
point mutations (66%) or small insertions/deletions (21%), whereas splicing mutations 
represent only 10% of the total and gross gene rearrangements are strikingly under-
represented (only 2 large deletions79,80 and 1 duplication81) (Figure 3). 
 
Figure 3. F5 mutational spectrum. 
Relative abundance of the different types of mutation in the F5 gene as reported in the Human 
Genome Mutation Database (accessed in March 2015). 
 
Remarkably, premature termination codons introduced by nonsense and frameshift mutations 
tend to cluster in exon 13, which encodes the large B domain. Splicing mutations, whose 
contribution to the mutational spectrum is probably underestimated, tend to be associated 
with severe clinical phenotypes, with a high incidence of life-threatening bleeding 
manifestations (e.g. intracranial haemorrhages).82-86 
 
Chapter 1 
 14 
In general, each family with FV deficiency has its own “private” F5 mutation. Only few 
mutations, such as Tyr1702Cys87 and Arg712Stop,88 have been found in several apparently 
unrelated patients. Therefore, F5 mutation screening needs to be carried out in each 
individual patient. Although all FV-deficient patients are treated in the same way 
irrespective of the underlying mutation(s), a molecular diagnosis may be desirable for the 
purposes of genetic counseling, prenatal diagnosis and (in perspective) personalized 
molecular therapy. 
 
Other bleeding disorders linked to the F5 gene 
The East Texas bleeding disorder89 is an autosomal dominant coagulopathy characterized by 
prolonged PT and APTT but normal values of all coagulation factors. Linkage analysis in the 
affected family pointed at F5 as the most likely candidate gene. Sequencing of this gene 
identified a mutation in exon 13 (2440A>G), which co-segregated with the bleeding 
phenotype. Further studies showed that this mutation up-regulates an alternatively spliced 
FV isoform called FV-short90 (Figure 4). This isoform lacks 702 amino acids of the B 
domain (residues 756-1458), including the basic region, leaving the acidic region fully 
available to interact with TFPIα.91 As a consequence, FV-short binds TFPIα with markedly 
higher affinity than full-length FV. FV-short is present in all individuals (accounting for 
~5% of all plasma FV with a large inter-individual variation), but its up-regulation by the 
2440A>G mutation results in 10-fold increased levels of plasma TFPIα and a bleeding 
tendency.  
More recently, a different mutation (F5 2678C>G, FV Amsterdam) was identified in a Dutch 
family with a similar bleeding disorder and normal levels of all coagulation factors.92 Also 
this second mutation enhances an alternative splicing event leading to a FV isoform with an 
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in-frame deletion of 623 amino acids within the B domain (residues 834-1458) and increased 
affinity for TFPIα. This “Amsterdam FV-short isoform” (Figure 4) does not seem to occur in 
normal individuals. 
EX 12 EX 14EX 13
FV-short Texas
donor splice site
(2440A>G)
FV-short Amsterdam
donor splice site
(2678C>G)
Common
acceptor splice site
EX 12
EX 12 EX 14
EX 14
∆2106 nt.
within exon 13
∆702 a.a.  within the B-domain
∆1869 nt.
within exon 13
∆623 a.a.  within the B-domain
FV-short Texas transcript
FV-short Amsterdam transcript
F5 pre-mRNA
 
Figure 4. FV-short splicing variants. 
Schematic representation of the portion of the F5 pre-mRNA that undergoes alternative splicing. The 
donor splice sites activated by the East Texas and Amsterdam mutations are shown in green and 
pink, respectively. The common acceptor splice site is shown in light blue. 
 
 
Outline of this thesis 
This thesis focuses on the molecular genetics of FV deficiency and on emerging therapeutic 
approaches. Conventional mutation screening strategies, based on the amplification and 
sequencing of each exon and its splicing junctions, fail to identify one or both mutations in 
10-20% of patients with severe FV deficiency. These patients may harbour gross gene 
rearrangements (which are invisible to direct sequencing of individual exons) or splicing 
mutations (which may be easily overlooked if “disguised” as synonymous/missense exonic 
mutations or if located deep in introns). Identifying the mutation(s) responsible for FV 
deficiency in each individual patient may be important not only for a better understanding of 
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the molecular mechanisms of the disease, but also for developing personalized molecular 
therapies. Particularly splicing mutations, which are often associated with a severe bleeding 
phenotype, are amenable to RNA therapy with mutation-specific antisense molecules. 
Chapter 2 of this thesis reviews the general mechanism of pre-mRNA splicing and the 
available options to modulate this process for therapeutic purposes. Chapter 3 describes the 
development and validation of an in-house multiplex ligation-dependent probe amplification 
(MLPA) assay for the detection of gross F5 gene rearrangements and its application to 14 
genetically unexplained FV-deficient patients. Chapter 4 is a preliminary report of a novel 
splicing mutation affecting the canonical donor splice site of F5 intron 3 in a FV-deficient 
patient with an extremely severe clinical presentation. Chapter 5 describes the identification 
and characterization of a F5 splicing mutation initially mistaken for a neutral (synonymous) 
polymorphism in a patient with severe FV deficiency. In addition, it illustrates the use of a 
morpholino antisense oligonucleotide for the correction of this splicing defect in an in vitro 
minigene model. Chapter 6 extends this concept by presenting the correction of a F5 deep-
intronic mutation using two types of antisense molecules (a morpholino oligonucleotide and 
an engineered small nuclear RNA) and two experimental models (a F5 minigene and the 
patient’s own megakaryocytes differentiated ex vivo from circulating hematopoietic 
progenitors). Chapter 7 illustrates the impact of plasma full-length TFPIα levels on the 
thrombin generation and bleeding tendency of two related FV-deficient patients homozygous 
for the same F5 missense mutation, pointing out TFPIα as a possible therapeutic target in 
severe FV deficiency. Finally, Chapter 8 integrates the information of all preceding chapters 
and discusses it in the context of current literature. 
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Abstract 
Factor V (FV) deficiency is a rare autosomal recessive bleeding disorder caused by 
mutations in the F5 gene. FV-deficient patients in whom no mutation or only one mutation is 
found may harbour large gene rearrangements, which are not detected by conventional 
mutation screening strategies. The aim of this study was to develop and validate a multiplex 
ligation-dependent probe amplification (MLPA) assay for the detection of large deletions 
and duplications in the F5 gene. Twenty-two MLPA probes targeting 19 of the 25 exons and 
the upstream and downstream regions of the F5 gene were designed and tested in 10 normal 
controls, a patient with a known heterozygous deletion of F5 exons 1-7 (positive control) 
and 14 genetically unexplained FV-deficient patients. MLPA results were confirmed by 
digital PCR on a QuantStudio™ 3D Digital PCR System. The F5-specific probes yielded a 
reproducible peak profile in normal controls, correctly detected the known deletion in the 
positive control and suggested the presence of a novel deletion of exons 9-10 in a patient 
with undetectable FV levels and only one identified mutation. Follow-up by chip-based 
digital PCR, long-range PCR and direct sequencing confirmed that this patient carried a 
heterozygous F5 deletion of 1823 bp extending from intron 8 to intron 10. Bioinformatics 
sequence analysis pinpointed repetitive elements that might have originated the deletion. In 
conclusion, we have developed and validated an MLPA assay for the detection of gross F5 
gene rearrangements. This assay may represent a valuable tool for the molecular diagnosis of 
FV deficiency. 
___________________________________________________________________________________ 
Note: The F5 gene mutations described in this chapter are annotated according to the HGVS recommendations. 
The corresponding annotation according to the classical nomenclature (Jenny et al. 1987) is as follows: 
HGVS nomenclature Classical nomenclature 
g.42208_44031del 
p.Ile433_Gln537del 
Deletion extends from nt. IVS8+1311 to nt. IVS10+378 
Deletion spans amino acids 405-509 
p.Phe551Ser Phe523Ser 
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Introduction 
Coagulation factor V (FV) deficiency is a rare autosomal recessive bleeding disorder 
associated with mutations in the F5 gene.1-3 The human F5 gene spans ~80 kb on the long 
arm of chromosome 1 (1q23) and comprises 25 exons. To date, ~150 point mutations and 
small insertions/deletions have been described in this gene. In contrast, only two large 
deletions have been reported: an interstitial deletion of chromosome 1q involving the 
(whole?) F5 gene in a 15-year-old girl (FV:C 9%) who carried a missense mutation 
(p.Ser262Trp) on the other F5 allele,4 and a heterozygous 205-kb deletion spanning F5 
exons 1-7 (plus the whole SELP, SELL and SELE genes) in a South-African baby (FV:C 1%) 
who carried a splicing mutation (F5 1975+5G>A) on the other allele.5 The remarkable 
under-representation of large deletions in the F5 mutational spectrum is probably due to the 
fact that gross gene rearrangements are invisible to conventional mutation screening 
strategies, which are based on the amplification and sequencing of individual exons. 
Multiplex ligation-dependent probe amplification (MLPA)6-8 is the technique of choice for 
the detection of copy-number variations in genes of interest. In this PCR-based gene dosage 
assay, the number of copies of specific target sequences in a genome is determined by 
comparison with reference sequences assumed to be present in two copies in the same 
genome. For each target and reference sequence, two oligonucleotides (i.e. a ‘probe’) are 
designed that anneal side by side to the template DNA. After incubating the probes with the 
genomic DNA sample, annealed oligonucleotides are ligated to generate products of 
different lengths, each corresponding to a target or reference sequence. Ligation products are 
then amplified using a pair of universal primers (one of which is fluorescently labelled) and 
PCR products are separated by capillary electrophoresis, yielding a characteristic peak 
profile. The height of each target peak relative to the heights of the reference peaks in the 
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same profile provides information on the number of copies of that particular target sequence 
in the DNA sample. 
Since no commercial MLPA probes for the F5 gene are available, we developed and 
validated an in-house MLPA assay with self-designed F5-specific probes, and applied it to 
the identification of gross gene rearrangements in genetically unexplained FV-deficient 
patients. 
 
Patients and Methods 
 
Study subjects 
Genomic DNA was obtained from the following subjects: a) 10 unrelated normal controls (5 
males and 5 females) used to assess the reproducibility of the F5 MLPA assay; b) a carrier of 
the described deletion of F5 exons 1-7 (i.e. the mother of the patient reported in ref.5), who 
served as a positive control to validate the assay; and c) 14 patients with severe (FV:C ≤5%, 
n=5) or partial (FV:C 11-48%, n=9) FV deficiency, in whom no mutation or only one 
mutation was identified by conventional mutation screening strategies. The study was 
approved by the local Ethical Committees and conducted according to the Helsinki 
Declaration. 
 
F5 MLPA assay 
MLPA probe design. Two sets of 11 F5-specific probes with lengths between 88 and 148 
nucleotides (nt) were designed according to the guidelines provided by MRC-Holland, 
Amsterdam, the Netherlands (www.mrc-holland.com) and purchased from Integrated DNA 
Technologies (Leuven, Belgium), as previously described.9 The first set (probe mix A) 
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includes probes for exons 1, 4, 7, 10, 13 (proximal portion), 16, 19, 22 and 24, as well as 
intron 3 and the 3’-UTR. The second set (probe mix B) includes probes for the promoter 
region as well as intron 2 and exons 6, 9, 11, 13 (distal portion), 14, 15, 17, 18 and 21. Each 
F5-specific probe mix was combined with a commercial reference probe mix (SALSA 
MLPA kit P200-A1 Human DNA Reference 1, MRC-Holland), which contains 14 probes 
(172-250 nt in length) mapping to other genes scattered over different chromosomes, 
including the X and Y chromosomes. The reference probe mix also contains control probes 
for DNA amount (Q-fragments, 64-82 nt) and for complete DNA denaturation during the 
MLPA reaction (D-probe, mapping to 14q32). 
MLPA reaction. MLPA ligation and amplification reagents were obtained from MRC-
Holland. MLPA reactions were carried out on 100 ng genomic DNA according to the 
manufacturer’s instructions. After adding GeneScan™ 600 LIZ® dye Size Standard and Hi-
Di™ formamide (Life Technologies, Bleiswijk, The Netherlands), amplification products 
were denatured at 80°C for 2 minutes and separated by capillary electrophoresis on an ABI 
3730 DNA Analyzer (Life Technologies). 
Peak analysis. Peak profiles were analysed using Coffalyser.Net software (MRC-Holland) 
and dosage quotients were calculated for each target (i.e. F5-specific) probe as follows. First, 
the height of each F5-specific peak was divided by the sum of the heights of all reference 
peaks in the same sample (except the peaks corresponding to the D-probe and to the sex 
chromosome probes). Then, the ratio obtained for each F5-specific probe in the test sample 
was divided by the corresponding ratio obtained in a control sample run in parallel. A dosage 
quotient of 0.8-1.15 is considered normal and indicates the presence of two copies of the 
corresponding target sequence. Dosage quotients of 0.35-0.65 and 1.35-1.55 indicate the 
 
Chapter 3 
 50 
presence of one copy (heterozygous deletion) and three copies (heterozygous duplication), 
respectively, of the corresponding target sequence. 
 
Digital PCR 
Digital PCR (dPCR)10,11 allows accurate quantification of nucleic acid templates by 
partitioning the PCR reaction mix over a large number of wells, so that each well contains a 
single copy or no copies of the target region. Based on the assumption of Poisson 
distribution of copies, the number of template copies originally present in the sample can be 
recalculated from the number of wells in which amplification has successfully occurred. 
dPCR was performed on a QuantStudio™ 3D Digital PCR System (Life Technologies). 
Reaction mixtures were prepared by combining 30 ng of genomic DNA with the 
QuantStudio™ 3D Digital PCR Master Mix and a custom TaqMan assay (Sigma-Aldrich, 
Milan, Italy) for F5 exon 10 (target) or F11 exon 5 (control). Each reaction mixture was 
loaded onto a QuantStudio™ 3D Digital PCR Chip, which contains 20,000 wells, and cycled 
under standard conditions for 40 cycles. End-point fluorescence data were collected and 
analysed using the QuantStudio™ 3D Digital PCR Instrument and the QuantStudio™ 3D 
AnalysisSuite™ according to the manufacturer’s instructions. 
 
Long-range PCR 
Long-range PCR was performed using the Expand Long Template PCR System Kit (Roche 
Applied Science, Almere, The Netherlands) according to the manufacturer’s instructions. 
The exact deletion breakpoints were mapped by direct sequencing of the PCR products. 
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Bioinformatics analysis 
The genomic region surrounding the newly identified deletion was analysed with 
RepeatMasker (www.repeatmasker.org) to look for repeated sequences that may have 
mediated the recombination event. Linkage disequilibrium within and around the F5 locus 
was visualised using Haploview.12 
 
Results 
 
Development and validation of the F5 MLPA assay 
To test the self-designed probes, the F5 MLPA assay was initially carried out on DNA 
samples from 10 normal controls. Both probe mixes yielded the expected peak profiles 
(Figure 1, upper panels) and the assay reproducibility in normal DNA samples was generally 
good (average coefficient of variation of normalised peak height: 11.9% for probe mix A and 
11.4% for probe mix B; average coefficient of variation of normalised peak area: 12.1% for 
probe mix A and 12.6% for probe mix B). Only the shortest probes of both probe mixes 
(corresponding to exon 1 and to the promoter region, respectively) occasionally produced 
double peaks, possibly due to the high GC-content of these probes. Since peak height was 
slightly more reproducible than peak area, we decided to rely on peak height for the 
quantitative analysis of peak profiles. 
When the F5 MLPA assay was applied to a positive control DNA sample carrying the 
previously described deletion of F5 exons 1-7,5 all F5-specific probes targeting sequences 
located upstream of intron 7 showed markedly decreased peaks (Figure 1, middle panels). 
Quantification of peak heights showed dosage quotients between 0.49 and 0.65 for these 
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probes and normal dosage quotients for all other probes (Figure 1, lower panels), indicating 
that the assay is indeed sensitive to copy number variations in the F5 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Validation of the in-house F5 MLPA assay in a positive control sample. 
The peak profiles obtained with probe mixes A (left) and B (right) in a normal control (upper panels) 
and in a positive control carrying the described deletion of F5 exons 1-7 (middle panels) are shown. 
Both individuals are female, as indicated by the absence of signal for the Y chromosome probe. The 
target and reference sequences recognised by each probe are indicated below the corresponding 
peaks. The peaks that are relatively lower in the positive control are indicated by arrows. Peak 
profiles were analysed as described under Methods and the dosage quotient of each probe was plotted 
in a bar diagram (lower panels). Probes with a dosage quotient between 0.35 and 0.65 (promoter 
region, exons 1, 4, 6 and 7, and introns 2 and 3), suggestive of a heterozygous deletion, are marked in 
black. 
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Identification and characterisation of a novel F5 large deletion 
We then analysed DNA samples from 14 FV-deficient patients in whom no mutation or only 
one mutation had been identified using conventional screening methods. One patient with 
severe FV deficiency (P10) showed remarkably low peaks for exons 9 and 10 (dosage 
quotients of 0.55 and 0.60, respectively), suggestive of a heterozygous deletion of these 
exons (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Detection of a novel F5 large deletion in a FV-deficient patient. 
The peak profiles obtained with probe mixes A (left) and B (right) in a normal control (upper panels) 
and in a patient with severe FV deficiency (P10, middle panels) are shown. Both individuals are 
male, as indicated by the successful amplification of the Y chromosome probe. The target and 
reference sequences recognised by each probe are indicated below the corresponding peaks. The 
peaks that are relatively lower in the patient are indicated by arrows. Peak profiles were analysed as 
described under Methods and the dosage quotient of each probe was plotted in a bar diagram (lower 
panels). Probes with a dosage quotient between 0.35 and 0.65 (exons 9 and 10), suggestive of a 
heterozygous deletion, are marked in black. 
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The presence of a deletion was verified by dPCR (Figure 3), which allows absolute 
quantification of copy numbers without reference to a standard curve.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Evaluation of the deletion in the F5 gene using dPCR. 
A) Histogram view of the results obtained with QuantStudio™ 3D AnalysisSuite™ (absolute 
quantification mode). Yellow peaks correspond to wells in which no amplification was detected; blue 
peaks indicate PCR-amplified spots. 
B) Graphic representation of the results of the assay. The number of copies of the target region is 
shown for both F5 and F11 assays. Bars represent the mean ± the precision of the assay as calculated 
by the software. 
 
F5 MLPA 
 55 
Analysis of the F11 gene, used as a control, showed that patient P10 and a normal control 
had the same number of F11 copies (on average 612 copies/μl and 648 copies/μl, 
respectively); conversely, analysis of the F5 gene revealed that the patient had half as many 
copies of F5 exon 10 as the normal control (on average 301 copies/μl vs. 611 copies/μl) 
(Figure 3). 
The deletion was further confirmed by long-range PCR using primers located in exons 7 and 
11 (Figure 4A), which had normal dosage quotients in the MLPA assay (Figure 2) and were 
therefore assumed to fall outside the deleted region. Amplification of this large genomic 
fragment yielded only the expected 8713-bp band in the normal control, but also a lower 
band (corresponding to the deleted allele) in the patient. In fact, the deleted allele was 
amplified much more efficiently than the normal allele, probably due to its considerable (~2 
kb) smaller size. In order to map the exact deletion breakpoints, nested PCR reactions were 
carried out using forward primers located progressively closer to exon 9, until the deleted 
allele failed to amplify and only the normal band was observed in the patient (Figure 4A). 
This indicated that the forward primer used in this reaction (IVS8cF) fell inside the deleted 
region and that the proximal breakpoint of the deletion was located between primers IVS8bF 
and IVS8cF. Direct sequencing of the patient’s IVS8bF-11R fragment eventually showed 
that the deletion (g.42208_44031del) encompassed 1823 bp of genomic sequence between 
introns 8 and 10  (Figure 4A). Bioinformatics analysis revealed that the deleted region was 
delimited by an AluJb sequence13 in intron 8 and a MIRc (mammalian-wide interspersed 
repeat, variant c) sequence14 in intron 10 (Figure 4A). These short interspersed elements 
(SINEs), which are extremely common in the human genome, share partial sequence 
homology and may have originated the deletion via misalignment of chromatids and 
homologous recombination at meiosis.15 
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C P B C P B C P B C P B C P B
7F-11R 8F-11R IVS8aF-11R IVS8bF-11R IVS8cF-11R
Ex 7 Ex 8 Ex 9 Ex 10 Ex 11
IVS 7 IVS 8 IVS 9 IVS 10
1823 bp
7F 11R
11R8F
11RIVS8aF
11RIVS8bF
11RIVS8cF
10.0 kb
8.0 kb
6.0 kb
5.0 kb
4.0 kb
3.5 kb
3.0 kb
2.5 kb
Intron 8 Intron 10
AluJb MIRc
8713 bp
6119 bp
5752 bp
5219 bp
4648 bp
 
Figure 4A. Characterisation of the newly identified F5 deletion. 
Schematic representation of the relevant portion of the F5 gene, showing the extension of the 
deletion, the positions of the repeated sequences (AluJb and MIRc) presumably responsible for the 
unequal homologous recombination event, and the PCR primers used to map the deletion. The 
expected length of each amplicon in base pairs (bp) is indicated. Bottom left: PCR products obtained 
with the different primer pairs in a normal control (C), in FV-deficient patient P10 (P) and in a no-
DNA control (blank, B). Bottom right: Sequencing chromatogram showing the junction between 
introns 8 and 10 in the deleted allele. 
 
 
Interestingly, the putative recombination event took place close to the region that separates 
the two main haploblocks of the F5 gene in the Caucasian population (Figure 4B). 
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F5 gene
Ex 10 Ex 9
Recombination
hot-spot
Figure 4B. Characterisation of the newly identified F5 deletion. 
Linkage disequilibrium plot of a portion of chromosome 1 generated using Haploview software and 
the genotype data of the CEU population (Utah residents of Caucasian descent). The plot shows that 
the region found to be deleted in patient P10 lies near a recombination hot-spot within the F5 gene. 
 
 
Discussion 
Approximately 10-20% of all FV-deficient patients remain genetically unresolved, as no 
mutation or only one mutation is found by amplification and sequencing of the F5 coding 
sequence and splicing junctions. These patients might harbour gross gene rearrangements, 
which are not detected by the conventional mutation screening strategies. Therefore, we have 
developed and validated an in-house MLPA assay for the detection of large deletions or 
duplications in the F5 gene. This assay showed good reproducibility in normal controls, 
correctly recognised a previously described deletion of F5 exons 1-7 and successfully 
identified a novel deletion of exons 9 and 10 in a partially unresolved FV-deficient patient. 
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This is the third large deletion to be described in the F5 gene and the second to be 
characterised in detail. In combination with the missense mutation (p.Phe551Ser, Paraboschi 
et al, manuscript in preparation) which had been previously identified by direct sequencing 
of the F5 gene and which is predicted to be damaging (SIFT score 0), this large deletion 
accounts for the patient’s severe FV deficiency. 
Since MLPA is considered an explorative technique, the deletion was verified using both 
dPCR and long-range PCR. Compared to conventional real-time qPCR, dPCR can easily 
resolve two-fold differences in template copy numbers and proved to be a very efficient and 
elegant method to confirm the existence of the deletion. Long-range PCR with progressively 
nested primers was instrumental in mapping the extent of the deletion, which caused the 
proximal portion of intron 8 to fuse with the distal portion of intron 10. Although this 
chimeric intron could be correctly spliced out of the primary transcript and the resulting 
mature mRNA, lacking exons 9 (100 bp) and 10 (215 bp), would maintain the correct 
reading frame, the encoded mutant protein would lack 105 amino acids in the A2 domain 
(p.Ile433_Gln537del) and is unlikely to be properly folded and secreted. 
Bioinformatics analysis suggested that the deletion might have originated via unequal 
crossing-over between two different but partially homologous SINEs located in introns 8 and 
10 of the F5 gene. Remarkably, a similar mechanism (homologous recombination between 
two AluY repeats) was also proposed to underlie the previously described deletion of F5 
exons 1-7.5 In fact, the role of transposable elements in mediating unequal crossing-overs 
and generating large deletions or duplications is well documented.15 For example, the 
relatively high frequency of large deletions observed in the antithrombin gene (SERPINC1) 
has been attributed to the large number of Alu repeats present in this gene.16 
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Gross gene rearrangements are believed to play a major role in the aetiology of human 
diseases, but tend to be under-explored because of the lack of straightforward techniques for 
their detection. The development of commercial MLPA assays for several coagulation-
related genes has led to the identification of large deletions/duplications in patients with 
various coagulation disorders, including haemophilia A17-19 and B,20 von Willebrand 
disease21,22 and the deficiencies of antithrombin,16,23-25 protein C25 and protein S.25-30 
Although gross rearrangements of the F5 gene may also be more prevalent than previously 
suspected, only one of the 14 genetically unexplained FV-deficient patients investigated in 
our study turned out to carry a large deletion. Possible causes of FV deficiency in the other 
patients, which had already been screened for mutations in the F5 coding region and splicing 
junctions, may be apparently synonymous mutations affecting splicing,31 deep-intronic 
splicing mutations,9 mutations in regulatory portions of the gene (promoter, 3’-untranslated 
region) and perhaps extragenic mutations. 
 
Conclusion 
We have designed and validated an in-house MLPA assay for the detection of gross F5 gene 
rearrangements. This assay may represent a valuable tool for the molecular diagnosis of FV 
deficiency. 
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Abstract 
Coagulation factor V (FV) deficiency is a rare autosomal recessive bleeding disorder caused 
by mutations in the F5 gene. Here, we report the identification of a novel homozygous 
splicing mutation (F5 c.373+2T>C) in a FV-deficient patient with a particularly severe 
bleeding phenotype. Since this variant affects the conserved +2 position of the donor splice 
site of intron 3, it is likely to impair F5 pre-mRNA splicing by causing exon 3 skipping 
and/or the activation of a nearby cryptic splice site. However, analysis of the patient’s F5 
cDNA could not be performed (yet). Correct splicing might be restored using a specifically 
modified U1 small nuclear RNA. 
 
 
 
 
 
 
 
 
 
 
 
 
_________________________________________________________________________________________ 
Note: The F5 gene mutation described in this chapter is annotated according to the HGVS recommendations. 
The corresponding annotation according to the classical nomenclature (Jenny et al. 1987) is as follows: 
HGVS nomenclature Classical nomenclature 
c.373+2T>C IVS3+2T>C 
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Coagulation factor V (FV) deficiency1,2 is a rare autosomal recessive bleeding disorder 
caused by deleterious mutations in the F5 gene, which spans ~80 kb on the long arm of 
chromosome 1 and contains 25 exons.3 Symptoms range from mucosal and post-traumatic 
bleeding, which are present in virtually all patients, to life-threatening intracranial and 
gastro-intestinal hemorrhages, which are rare and confined to the most severe cases.4 
FV-deficient patients show a large genetic heterogeneity, each family having its own private 
mutation. In fact, >100 different F5 mutations have been described to date, the majority of 
which are missense or nonsense variants. Splicing mutations represent only ~10% of the F5 
mutational spectrum, but they tend to be associated with severe bleeding manifestations.5-11 
In this study we investigated the molecular basis of FV deficiency in an 18-month-old 
Omani girl (FV:C <1%) that came to clinical attention because of multiple intracranial 
hemorrhages in the first days of life. Despite immediate prophylaxis with fresh frozen 
plasma twice weekly, she experienced an additional intracranial bleeding while on 
prophylaxis. Since then, her prophylactic regimen has been upgraded to three fresh frozen 
plasma infusions per week. However, this could not prevent global developmental delay as a 
result of the previous bleeding events. Her parents are consanguineous (Figure 1). 
After obtaining informed consent, blood was collected from the proband and her family 
members at Sultan Qaboos University Hospital (Muscat, Sultanate of Oman) in compliance 
with local ethical regulations. Citrated plasma and genomic DNA were shipped to Maastricht 
for further analysis. The study was conducted according to the Helsinki Declaration. 
Direct sequencing of the proband’s F5 coding region and splicing junctions detected a novel 
homozygous mutation (F5 c.373+2T>C), affecting the second nucleotide of intron 3 (Figure 
1) and therefore likely to impair pre-mRNA splicing. Both parents (I-1 and I-2) and the 
proband’s eldest sister (II-1) were heterozygous for the same mutation, whereas the 
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proband’s other sister (II-2) did not carry the mutation. The observed F5 c.373+2T>C 
genotypes were consistent with the plasma FV antigen and activity levels determined by 
ELISA (Zymutest Factor V ELISA kit, NODIA, Amsterdam, The Netherlands) and by a 
sensitive prothrombinase-based assay, respectively (Figure 1). In particular, hardly any FV 
antigen and no FV activity could be detected in the proband’s plasma.  
I
II
FV:Ag 27.0%
FV:Act 37.2%
FV:Ag 27.6%
FV:Act 25.7%
FV:Ag 47.8%
FV:Act 33.4%
FV:Ag 83.7%
FV:Act 96.7%
FV:Ag 2.2%
FV:Act <0.5%
I-1 I-2
II-1 II-2 II-3
 
Figure 1. Pedigree of the FV-deficient family, F5 genetic analysis and FV levels. 
The proband is marked by an arrow. Carriership of the F5 c.373+2T>C mutation, as illustrated by the 
sequencing chromatograms of the F5 exon 3/intron 3 junction, is indicated by half-closed 
(heterozygosity) or closed (homozygosity) symbols. Plasma FV antigen (FV:Ag) and activity 
(FV:Act) levels are reported below each subject. 
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The F5 c.373+2T>C mutation affects positon +2 of the canonical donor splice site of intron 
3, reducing its complementarity to the U1 small nuclear RNA (U1snRNA), which normally 
recognizes the donor splice site during pre-mRNA splicing. In silico analysis indicated that 
the mutation reduces the donor splice site consensus score from 0.99 to undetectable 
(according to the NNsplice software) or from 0.96 to 0.69 (according to the Human Splicing 
Finder software) (Figure 2A). 
EX 2 EX 3 EX 45’ 3’
5’ - ...AAATTATCAGAAGGTAAGATAAATCTAATA... - 3’
Exon 3 Intron 3
Normal F5 sequence
F5 c.373T>C mutation
(IVS3+2T>C)
0.99 / 0.96  
5’ - ...AAATTATCAGAAGGCAAGATAAATCTAATA... - 3’
ND / 0.69 
EX 4EX 2
∆EX 3
(123 nt)
Normal mRNA
Aberrant mRNA
A
B
U1snRNA
EX 2 EX 3 EX 45’ 3’
F5 pre-mRNA
EX 2 EX 3 EX 4
IVS 2 IVS 3
Normal protein
Deletion of 41 amino acids in A1 domain
?
 
Figure 2. In silico analysis of the F5 c.373+2T>C mutation and possible splicing correction 
strategy. 
A) Schematic representation of the genomic region surrounding the F5 c.373+2T>C mutation (in 
red). The donor splice site consensus scores of the normal and mutated sequences, provided by the 
NNsplice/Human Splicing Finder softwares, are indicated below each sequence. ND, not detectable. 
B) Predicted effect of the F5 c.373+2T>C mutation on pre-mRNA splicing (exon 3 skipping) and 
possible strategy to restore correct splicing using an engineered U1snRNA (in green) specifically 
modified to recognise the mutated donor splice site. 
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Since position +2 is part of the absolutely conserved GT dinucleotide of the donor splice site 
consensus sequence (MAG/GTRAGT),12 the mutation is predicted to disrupt F5 pre-mRNA 
splicing. Abolition of a canonical donor splice site most often results in skipping of the 
preceding exon, unless nearby cryptic splice sites can take over the donor splice site 
function.13,14 Accordingly, the most likely consequence of the F5 c.373+2T>C mutation is 
skipping of exon 3 (123 nt), also in view of the fact that this alternative splicing event occurs 
in normal individuals as well.9 The resulting mRNA would maintain the correct reading 
frame, but it would encode a mutant FV lacking 41 amino acids in the A1 domain (Figure 
2B), which is unlikely to be correctly folded and secreted. Alternatively, activation of a pre-
existing cryptic splice site located upstream or downstream of the mutated splice site would 
result in partial deletion of exon 3 or partial retention of intron 3, probably leading to a 
frameshift and premature stop codon. Unfortunately, however, we have not (yet) been able to 
obtain a new blood sample from the proband for F5 cDNA analysis. On the other hand, 
cloning of a F5 minigene suitable to study the effects of the c.373+2T>C mutation on pre-
mRNA splicing is hampered by the large size of F5 intron 3 (>11 kb). 
The proband’s extremely severe clinical phenotype, requiring life-long prophylaxis with 
fresh frozen plasma three times a week (with consequent circulatory overload), justifies the 
search for alternative therapeutic options. Since the mutation disrupts a donor splice site, it 
might be targeted with antisense therapy using an engineered U1snRNA specifically 
modified to perfectly match the mutated splice site and thereby restore correct splicing  
(Figure 2B). The feasibility of this approach has been already shown for other splicing 
mutations responsible for coagulation factor deficiencies.15-17 However, mutations affecting 
position +2 of the donor splice site tend to be resistant to U1snRNA-mediated splicing 
correction.16,18 
 
Novel F5 splicing mutation 
 69 
In conclusion, this preliminary study confirms the association between F5 splicing mutations 
and severe clinical manifestations of FV deficiency. The exact impact of the F5 c.373+2T>C 
mutation on pre-mRNA splicing awaits experimental investigation by F5 cDNA analysis in 
the proband and/or in a minigene model. The latter would also offer the possibility to test the 
efficacy of therapeutic strategies based on engineered U1snRNA. 
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Abstract 
Coagulation factor V (FV) deficiency is a rare autosomal recessive bleeding disorder. We 
investigated a patient with severe FV deficiency (FV:C <3%) and moderate bleeding 
symptoms. Thrombin generation experiments showed residual FV expression in the patient’s 
plasma, which was quantified as 0.7 ± 0.3% by a sensitive prothrombinase-based assay. F5 
gene sequencing identified a novel missense mutation in exon 4 (c.578G>C, p.Cys193Ser), 
predicting the abolition of a conserved disulphide bridge, and an apparently synonymous 
variant in exon 8 (c.1281C>G). The observation that half of the patient’s F5 mRNA lacked 
the last 18 nucleotides of exon 8 prompted us to re-evaluate the c.1281C>G variant for its 
possible effects on splicing. Bioinformatics sequence analysis predicted that this transversion 
would activate a cryptic donor splice site and abolish an exonic splicing enhancer. 
Characterization in a F5 minigene model confirmed that the c.1281C>G variant was 
responsible for the patient’s splicing defect, which could be partially corrected by a 
mutation-specific morpholino antisense oligonucleotide. The aberrantly spliced F5 mRNA, 
whose stability was similar to that of the normal mRNA, encoded a putative FV mutant 
lacking amino acids 427-432. Expression in COS-1 cells indicated that the mutant protein is 
poorly secreted and not functional. In conclusion, the c.1281C>G mutation, which was 
predicted to be translationally silent and hence neutral, causes FV deficiency by impairing 
pre-mRNA splicing. This finding underscores the importance of cDNA analysis for the 
correct assessment of exonic mutations. 
___________________________________________________________________________________ 
Note: The F5 gene mutations described in this chapter are annotated according to the HGVS recommendations.  
The corresponding annotation according to the classical nomenclature (Jenny et al. 1987) is as follows: 
HGVS nomenclature Classical nomenclature 
c.578G>C (p.Cys193Ser) 668G>C (Cys165Ser) 
c.1281C>G (p.Val427_Lys432del) 1371C>G (Deletion spans amino acids 399-404) 
c.1285G>T 1375G>T 
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Introduction 
Factor V (FV)1,2 is an essential clotting factor present in plasma (~80%) and platelets 
(~20%). It is produced in the liver and secreted in plasma as a single-chain protein with the 
same domain structure as factor VIII (A1-A2-B-A3-C1-C2). Limited proteolysis by 
thrombin or factor Xa converts FV to its active form (FVa), which acts as a non-enzymatic 
cofactor in prothrombin activation and accelerates this reaction >1000-fold. FVa activity is 
down-regulated by activated protein C (APC)-mediated proteolysis of the heavy chain. 
Experiments in mice have shown that the complete absence of FV is not compatible with 
life,3 but traces of FV are sufficient to rescue the perinatal lethality of FV-/- mice.4 
In humans, FV deficiency is a rare autosomal recessive bleeding disorder.5-7 The most 
common symptoms are mucosal and post-traumatic bleeding, while haemarthroses and 
muscle haematomas are less frequently observed and life-threatening haemorrhages are 
rare.8 Residual platelet FV is a better predictor of clinical severity than plasma FV9-11 and 
plasma tissue factor pathway inhibitor (TFPI) levels may act as an additional phenotype 
modulator.12 
FV deficiency is caused by F5 gene mutations, of which ~150 have been described to 
date.13,14 Splicing mutations currently represent only ~10% of the F5 mutational spectrum, 
but their proportion is likely to be underestimated, because many splicing mutations fail to 
be identified. In fact, deep-intronic mutations that activate intronic pseudo-exons15 are not 
detected by conventional mutation screening strategies, which focus on the coding region of 
the gene. Moreover, exonic mutations that are translationally silent or predict a conservative 
amino acid change are usually dismissed as neutral or benign, whereas they might activate 
cryptic splice sites or alter splicing regulatory sequences, such as exonic splicing enhancers 
 
Chapter 5 
 76 
(ESEs) and silencers (ESSs).16-18 Such splicing defects can only be detected by cDNA 
analysis, which is however not routinely performed. 
Here we report an apparently synonymous F5 variant which, far from being neutral, causes 
aberrant splicing and virtually abolishes protein expression. 
 
Materials and Methods 
 
Blood collection and work-up 
The study was approved by the Human Subjects Committee of the University of North 
Carolina and was conducted in accordance with the Declaration of Helsinki. After obtaining 
the patient’s informed consent, blood was drawn in 3.2% citrate (9/1, vol/vol) and 
centrifuged at 2500g for 15 minutes to prepare platelet-poor plasma, which was stored at -
80°C. 
 
Thrombin generation 
Thrombin generation was measured in platelet-poor plasma with the Calibrated Automated 
Thrombogram (CAT) method,19 essentially as described.12 
 
Measurement of FV levels 
Plasma FV antigen level was measured using an in-house ELISA based on commercial 
polyclonal antibodies (Affinity Biologicals, Ancaster, ON, Canada). Plasma FV activity was 
measured with a prothrombinase-based assay, as described.12 The assay was performed in 8-
fold on independent plasma dilutions and calibrated with pooled normal plasma. The 
detection limit of this assay in plasma is ~0.5%.12 
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Genomic DNA analysis 
Genomic DNA was isolated from peripheral blood leukocytes by salting-out. All 25 exons 
and splicing junctions of the F5 gene were amplified and sequenced as previously 
described.11 
 
F5 cDNA analysis 
Blood was collected from the patient and two normal controls in PAXgene Blood RNA tubes 
(PreAnalytiX GmbH, Hombrechtikon, Switzerland). Total RNA was isolated using TRIzol 
Reagent (Invitrogen, Breda, The Netherlands) and reverse-transcribed using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Bedford, MA, USA), as 
described before.11 The F5 cDNA was amplified in 20 overlapping fragments, each spanning 
at least one splicing junction, and analysed by agarose gel electrophoresis. F5 cDNA 
fragments spanning exons 8-10 were excised from gel, purified with the QIAquick Gel 
Extraction Kit (Qiagen, Venlo, The Netherlands) and sequenced. 
 
In silico sequence analysis 
The impact of the F5 c.1281C>G mutation on splice site and regulatory sequences was 
investigated in silico using NNSPLICE version 0.9 
(http://www.fruitfly.org/seq_tools/splice.html), Human Splicing Finder 
(http://www.umd.be/HSF/)20 and ESE Finder 3.0 (http://rulai.cshl.edu/tools/ESE/).21 
 
F5 minigene model 
The effects of the F5 c.1281C>G (natural) and 1285G>T (control) mutations on pre-mRNA 
splicing were studied using a minigene model, as previously described.22 To this end, a wild-
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type genomic fragment encompassing F5 exon 8, intron 8 and exon 9 (g.40512-43071) was 
cloned within the FN1 intron of the pTB vector. The c.1281C>G and c.1285G>T mutations 
were separately introduced in the wild-type construct by site-directed mutagenesis 
(QuikChange II XL Site-Directed Mutagenesis Kit, Agilent Technologies, Amstelveen, The 
Netherlands) and the sequences of all three constructs were verified by direct sequencing. 
COS-1 and HepG2 cells were cultured as described before.22 Cells were seeded in 6-well 
plates and transiently transfected with 3 μg of wild-type or mutant F5 minigene construct 
using Lipofectamine2000 (Invitrogen). After 48 hours, cells were harvested in TRIzol Reagent 
(Invitrogen) and total RNA was isolated and reverse-transcribed. F5 minigene mRNA was 
specifically amplified using primers located in F5 exon 8 and in the distal FN1 exon of the 
pTB vector, and the splicing pattern was analysed by agarose gel electrophoresis. 
A 25-mer phosphorodiamidate morpholino oligonucleotide (PMO) complementary to the F5 
pre-mRNA bearing the c.1281C>G mutation and covering the mutation site and the putative 
ESE element (5’-TGTGTCTCTCACCTGGGCTCTGATA-3’, g.40867-40891, mutation site 
underlined) was obtained from GeneTools (Philomath, OR, USA). The ability of this 
antisense PMO (“rescuer”) to correct the splicing defect induced by the c.1281C>G mutation 
was tested in COS-1 and HepG2 cells transfected with the F5 1281G minigene construct. A 
similar PMO with an irrelevant sequence (“control”) was used as a negative control. PMOs 
(0-20 μM) were administered to cells using EndoPorter Reagent in aqueous formulation (6 
μM), essentially as described.22 After 48 hours, cells were harvested in TRIzol Reagent and 
mRNA was isolated, reverse-transcribed and analysed by PCR and agarose gel 
electrophoresis. 
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Recombinant FV expression 
The c.578G>C mutation and the deletion of codons 427-432 were introduced in the 
pMT2/FV construct by site-directed mutagenesis. Successful mutagenesis was confirmed by 
direct sequencing. COS-1 cells were seeded in 6-well plates and transiently transfected with 
3 μg of wild-type or mutant pMT2/FV construct using Lipofectamine2000 (Invitrogen). 
Conditioned media were collected 48 hours post-transfection, centrifuged at 2000g for 10 
minutes and analysed for FV antigen (ELISA) and activity (prothrombinase-based assay). 
FV antigen and activity levels from quadruplicate transfections were averaged and mock 
medium was used as a negative control. Control experiments in which known amounts of 
purified FV were added to mock medium indicated that the prothrombinase-based test can be 
reliably performed on the background of (conditioned) medium. 
 
Results 
 
Case history 
The patient is a 20-year-old male with severe FV deficiency (FV:C <3%). Because he was 
adopted, little is known about his early medical history. The diagnosis of FV deficiency was 
made at the age of 15 years, when he presented with prolonged epistaxis. Subsequently, he 
was treated with fresh frozen plasma for several muscle bleeds induced by mild trauma. 
The patient had not received any fresh frozen plasma or platelet concentrates in the three 
months preceding blood collection for the present study. 
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Thrombin generation and FV levels 
To assess the patient’s overall coagulation potential, thrombin generation was measured in 
the patient’s plasma and control plasma triggered with 1-50 pM TF (Figure 1A,B). Thrombin 
generation in the patient’s plasma was detectable at all TF concentrations, suggesting that the 
patient has residual FV expression. To prove this, thrombin generation was re-measured at 
10 pM TF in the absence and presence of increasing concentrations of APC (Figure 1C,D), 
the specific inhibitor of FVa. APC progressively reduced thrombin generation in control 
plasma and completely abolished thrombin generation in the patient’s plasma, indicating that 
the thrombin generation observed in the absence of APC was indeed supported by FV. 
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Figure 1. Thrombin generation in patient’s plasma.  
Platelet-poor plasma from a normal control (A,C) and from the FV-deficient patient (B,D) was 
activated with the indicated concentrations of TF and thrombin generation was measured by 
Calibrated Automated Thrombography. A,B: TF-titration (1-50 pM) of thrombin generation in the 
absence of APC. C,D: APC-titration (0-6 nM) of thrombin generation triggered with 10 pM TF. 
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The FV antigen level in the patient’s plasma was 0.4%. The FV activity level, as determined 
in 8-fold using a very sensitive prothrombinase-based assay in highly diluted plasma, was 
found to be significantly different from the blank and quantified as 0.7±0.3% of normal 
plasma. 
 
Genetic analysis 
F5 mutation screening identified two novel heterozygous transversions in the patient’s DNA: 
c.578G>C in exon 4 and c.1281C>G in exon 8. The former predicts the substitution of 
Cys193 by a Ser and consequent destruction of a disulfide bridge (Cys167-Cys193) within the 
A1 domain of FV. The latter does not predict an amino acid change (Val427Val) and is 
located far from splicing junctions. Therefore, it was initially regarded as a rare neutral 
variant. 
Since the p.Cys193Ser mutation alone could not explain the patient’s barely detectable FV 
levels, F5 cDNA analysis was performed to check for possible splicing defects. 
Amplification of a F5 cDNA fragment spanning exons 8-10 yielded only the expected 269-
bp product in two normal controls, but an additional - smaller - product in the patient (Figure 
2), suggesting that half of the patient’s F5 mRNA was spliced incorrectly in this region. 
Sequencing of the aberrant cDNA fragment indicated that this lacked the last 18 nucleotides 
of exon 8 (Figure 2). As judged from the intensity of the gel bands, this in-frame deletion did 
not compromise the stability of the aberrantly spliced mRNA. 
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Figure 2. F5 cDNA analysis. 
Total RNA was isolated from the patient’s blood cells and reverse-transcribed to cDNA. A F5 cDNA 
fragment spanning exons 8-10 was amplified in the patient (P) and in two normal controls (C1, C2) 
and analysed by agarose gel electrophoresis (left) and direct sequencing (right). M,molecular weight 
marker. The patient’s aberrantly spliced cDNA lacks the last 18 nucleotides (nt) of exon 8. 
Noteworthy, the 1281 position is normal (C) in the correctly spliced transcript and falls in the deleted 
region in the aberrantly spliced transcript. 
 
Bioinformatics sequence analysis 
F5 exon 8 was analysed in silico for the presence of splice site consensus and regulatory 
sequences, and the c.1281C>G mutation was re-evaluated for its possible impact on pre-
mRNA splicing (Figure 3A). This analysis showed that the c.1281C>G mutation activates a 
cryptic donor splice site in exon 8, increasing its consensus score from 0.81 in the absence of 
the mutation to 0.97 in the presence of the mutation (NNSPLICE software) or from 92.64 to 
96.51 (Human Splicing Finder software). Due to its high consensus score, this splice site 
may effectively compete with the canonical donor splice site (consensus score of 0.98 and 
88.47 according to the NNSPLICE and Human Splicing Finder softwares, respectively). In 
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addition, the c.1281C>G mutation destroys a putative ESE sequence recognised by the trans-
acting splicing factor SRSF2 (consensus motif: GRYYcSYR), which might contribute to 
define exon 8. As a consequence, in the presence of the mutation, the cryptic splice site is 
predicted to become the preferred donor splice site for intron 8, resulting in the deletion of 
18 nucleotides from the mature mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A. Bioinformatic analysis of the c.1281C>G and c.1285G>T mutations. 
In silico analysis of the F5 sequence surrounding the c.1281C>G mutation for the presence of splice 
site consensus sequences (top) and splicing regulatory elements (bottom). Identified donor splice site 
consensus sequences are boxed and the corresponding consensus scores (provided by the NNSPLICE 
/ Human Splicing Finder softwares) are reported underneath. The cryptic donor splice site present in 
the wild-type sequence is boxed with a dashed line. The putative exonic splicing enhancer (ESE) 
element is underlined and its score (provided by the ESE Finder software by comparison with the 
consensus sequence GRYYcSYR) is reported underneath. ND, not detectable (i.e. below the 
threshold of 2.383). Exonic sequence is shown in black, intronic sequence in grey. Mutated 
nucleotides are shaded in light grey. 
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Characterisation of the c.1281C>G mutation in a minigene model 
To prove that the c.1281C>G mutation causes the splicing abnormality observed in the 
patient’s F5 cDNA, we transfected COS-1 and HepG2 cells with F5 minigene constructs 
containing exon 8 (without or with the c.1281C>G mutation), intron 8 and exon 9, and 
analysed the splicing pattern of the transcribed mRNA. While the wild-type minigene 
produced only the correctly spliced mRNA, the 1281G minigene produced predominantly 
aberrantly spliced mRNA, lacking the last 18 nucleotides of F5 exon 8 (Figure 3B), which 
indicates that the c.1281C>G mutation is indeed responsible for the splicing defect observed 
in the patient’s F5 mRNA. Remarkably, very little residual correct splicing was observed in 
the presence of the c.1281C>G mutation, despite the fact that the canonical donor splice site 
is still intact. This suggested that disruption of the ESE sequence might also contribute to the 
shift in splicing pattern induced by the c.1281C>G mutation. To verify whether the ESE 
element is required for the recognition of the canonical donor splice site, we devised a 
control mutation (c.1285G>T) which destroys the ESE element (Figure 3A) without creating 
an alternative donor splice site or altering the consensus score of the canonical donor splice 
site. When this mutation was introduced in the wild-type F5 minigene and expressed in 
COS-1 or HepG2 cells, only correctly spliced mRNA was observed (Figure 3B), indicating 
that the ESE element is unlikely to contribute to exon 8 definition.  
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Figure 3B. Splicing assays of the c.1281C>G and c.1285G>T mutations. 
 HepG2 cells were transfected with the F5 wild-type (WT), 1281G or 1285T minigene constructs, 
and output mRNA was analysed 48 hours post-transfection. Results of duplicate transfections are 
shown. Similar results were obtained in COS-1 cells (not shown). Blanks, reverse-transcription blank 
and PCR blank. M, molecular weight marker. In the scheme, the sequence of 18 nucleotides that is 
deleted in the aberrantly spliced mRNA is hatched. 
 
 
Splicing defects can be corrected by antisense-based RNA therapy,23,24 which makes use of 
specific antisense oligonucleotides to hide incorrect splicing signals on the pre-mRNA. To 
test whether the F5 c.1281C>G mutation is amenable to antisense-based therapy, cells 
transfected with the F5 1281G minigene construct were treated with a mutation-specific 
(rescuer) PMO (Figure 4). Increasing concentrations of this PMO caused progressive 
normalisation of the splicing pattern, reaching a correction level of ~50% at 20 μM rescuer 
PMO (Figure 4). In contrast, no correction of the splicing defect was observed with the same 
concentration of control PMO (Figure 4). 
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Figure 4. Correction of the splicing pattern by phosphorodiamidate morpholino 
oligonucleotides (PMO). 
Top: Schematic representation of the mutant F5 pre-mRNA, including the distal portion of exon 8 
(boxed black sequence) with the c.1281C>G mutation (red) and the proximal portion of intron 8 
(grey sequence). The nucleotides that are part of the cryptic splice site and/or ESE consensus 
sequences are highlighted in grey. The rescuer PMO (boldface sequence) is shown hybridised to the 
pre-mRNA. 
Bottom: HepG2 cells were transfected with the F5 wild-type (WT) or 1281G minigene constructs 
and treated with the indicated concentrations of rescuer (R) or control (C) PMO, and output mRNA 
was analysed 48 hours post-transfection. Similar results were obtained in COS-1 cells (not shown). 
Blanks, reverse-transcription blank and PCR blank. M, molecular weight marker. 
 
 
Expression and characterisation of FV mutants 
The patient’s aberrantly spliced F5 mRNA lacks the last 18 nucleotides of exon 8, 
corresponding to the codons for amino acids 427-432 in the A2 domain of FV. Since this 
deletion does not affect the reading frame, it does not target the mRNA for degradation by 
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the nonsense-mediated decay pathway,25 allowing for the possibility that the aberrant mRNA 
is translated into a protein, which however may not be stable and/or secretable. To check 
whether the mutant protein is expressed at all, a pMT2/FV construct lacking codons 427-432 
was created and expressed in COS-1 cells. Analysis of the conditioned media revealed some 
FV antigen (11.6±1.6% of wild-type FV, p<0.001 vs. mock medium) but no FV activity 
(0.18±0.02% of wild-type FV, p=n.s. vs. mock medium), indicating that the aberrantly 
spliced F5 mRNA does not encode a functional protein. 
Finally, the FV p.Cys193Ser mutant was also expressed as a recombinant protein. The FV 
antigen level in the conditioned media was 2.6±0.3% (p<0.001 vs. mock medium), whereas 
FV activity was barely detectable (0.32±0.09% of wild-type FV, p=0.017 vs. mock medium). 
 
Discussion 
Patients with plasma FV levels in the 0-5% range are expected to be homozygous or 
compound heterozygous for F5 mutations, but 10-20% of cases remain genetically 
unexplained.26 Failure to identify one or both mutations by direct sequencing of the coding 
region may signify the presence of gross gene rearrangements26,27 or deep-intronic splicing 
mutations,11 which are not detected by conventional mutation screening strategies. 
Alternatively, it may be due to misclassification of exonic variants, which are typically 
assessed only on the basis of their predicted effects on translation, whereas they may just as 
well impair pre-mRNA splicing, as recently shown for missense mutations in the FGB and 
F11 genes28,29 as well as for a synonymous mutation in the LMAN1 gene.30 In fact, evidence 
is accumulating that synonymous variants significantly contribute to human disease by 
affecting not only pre-mRNA splicing, but also mRNA stability and translation efficiency.31 
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In this study, we present a patient with hardly detectable FV levels and apparently only one 
detrimental F5 mutation (c.578G>C, predicting the p.Cys193Ser substitution in the A1 
domain). Cys193 is evolutionarily conserved from zebrafish to human, as well as in the A1 
domains of factor VIII and ceruloplasmin, and forms an intra-domain disulfide bridge with 
equally conserved Cys167.32 Abolition of this disulfide bridge by the p.Cys193Ser mutation is 
likely to impair folding of the A1 domain and to compromise the stability and/or secretion of 
the mutant FV, as confirmed by the expression experiments. 
The second F5 variant identified in the patient (c.1281C>G in exon 8) was initially 
considered a rare neutral polymorphism, because it does not predict an amino acid change 
and it is located far from splicing junctions. However, a closer examination led us to 
establish that the F5 c.1281C>G mutation actually affects pre-mRNA splicing, based on the 
following evidence: a) the observation that half of the patient’s F5 mRNA lacks the last 18 
nucleotides of exon 8, while this deletion is not present in the patient’s genomic DNA; b) the 
in silico prediction that the c.1281C>G mutation activates a cryptic donor splice site (and 
abolishes a putative ESE element) in exon 8; c) the finding that cells transfected with the F5 
1281G minigene construct produce almost exclusively aberrantly spliced mRNA; and d) the 
ability of a mutation-specific antisense PMO to restore correct splicing of the mutant pre-
mRNA. In contrast to the deep-intronic mutation that we targeted in a previous study,22 the 
c.1281C>G mutation is located in an exon and the corresponding antisense PMO covers 25 
nucleotides of exonic sequence and extends up to 6 nucleotides from the canonical donor 
splice site. This proximity may explain the incomplete correction of the splicing pattern even 
at relatively high PMO concentrations (20 μM), as observed for similar exonic mutations in 
the ATM gene.33 Nonetheless, antisense-based RNA therapy might represent an alternative 
therapeutic option for this patient. The fact that disruption of the ESE sequence (as in the F5 
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1285T minigene) or its masking by the rescuer PMO is compatible with correct splicing 
suggests that this element is not required for recognition of the canonical donor splice site. 
Alternatively, the spliceosome and the splicing factor SRSF2 may compete for binding to the 
overlapping cryptic splice site/ESE sequences and the c.1281C>G mutation might tip the 
balance in favour of the spliceosome. 
Since deletion of the last 18 nucleotides of exon 8 did not alter its reading frame or stability, 
the aberrantly spliced F5 mRNA could be theoretically translated into a viable protein 
lacking amino acid residues 427-432 in the A2 domain. However, expression of the 
aberrantly spliced mRNA in COS-1 cells resulted in poor protein secretion and undetectable 
FV activity in conditioned media, suggesting that the deleted protein is grossly misfolded 
and hence largely retained/degraded within the cell. In addition, these findings confirm that 
the c.1281C>G mutation, which causes the splicing aberration, is the second mutation 
responsible for the patient’s FV deficiency. 
 
Conclusion 
The FV-deficient patient investigated here is doubly heterozygous for the F5 c.578G>C 
(p.Cys193Ser) and c.1281C>G (splicing) mutations, which are both causative and together 
explain the barely detectable FV level in the patient’s plasma. Residual FV expression in the 
patient (<1%) is most probably attributable to a small percentage of normal splicing of the 
1281G allele. Given the extremely low FV requirement for minimal haemostasis,4,10,34 
residual FV expression, in combination with the low plasma level of full-length TFPI (35.5% 
of pooled normal plasma, data not shown),12 explains the comparatively moderate bleeding 
tendency of this patient. 
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Overall, our findings illustrate how an exonic variant, predicted to be translationally silent 
and hence neutral, can actually be detrimental by disrupting the splicing code and impairing 
pre-mRNA processing. This underscores the importance of cDNA analysis for the correct 
assessment of exonic mutations and may have implications for the annotation of exonic 
variants identified by next-generation sequencing. 
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Abstract 
Antisense molecules are emerging as a powerful tool to correct splicing defects. Recently, 
we identified a homozygous deep-intronic mutation (F5 c.1296+268A>G) activating a 
cryptic donor splice site in a patient with severe coagulation factor V (FV) deficiency and 
multiple life-threatening bleeding episodes. Here we assessed the ability of two mutation-
specific antisense molecules (a morpholino oligonucleotide (MO) and an engineered 
U7snRNA) to correct this splicing defect. COS-1 and HepG2 cells transfected with a F5 
minigene construct containing the patient’s mutation expressed aberrant mRNA in excess of 
normal mRNA. Treatment with mutation-specific antisense MO (1-5 μM) or a construct 
expressing antisense U7snRNA (0.25-2 μg) dose-dependently increased the relative amount 
of correctly spliced mRNA up to ~30-fold and ~100-fold, respectively, whereas control MO 
and U7snRNA with irrelevant sequences were ineffective. Patient-derived megakaryocytes 
obtained by differentiation of circulating progenitor cells did not express FV, but became 
positive for FV at immunofluorescence staining after administration of antisense MO or 
U7snRNA. However, treatment adversely affected cell viability, mainly because of the 
transfection reagents used to deliver the antisense molecules. Our data provide in vitro and 
ex vivo proof-of-principle for the efficacy of RNA therapy in severe FV deficiency, but 
additional cytotoxicity studies are warranted. 
 
 
 
___________________________________________________________________________________ 
Note: The F5 gene mutation described in this chapter is annotated according to the HGVS recommendations. 
The corresponding annotation according to the classical nomenclature (Jenny et al. 1987) is as follows: 
HGVS nomenclature Classical nomenclature 
c.1296+268A>G IVS8+268A>G 
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Introduction 
Coagulation factor V (FV) is a large glycoprotein produced in the liver and released in the 
bloodstream as an inactive precursor. Once activated, it acts as a non-enzymatic cofactor of 
factor Xa (FXa) in the conversion of prothrombin (PT) to thrombin, accelerating this 
reaction by several orders of magnitude.1 This essential role in thrombin formation makes 
FV indispensable to life, as demonstrated by the lethal phenotype of FV knock-out mice.2 
Approximately 80% of FV circulates in plasma, the remaining 20% being stored in platelet 
α-granules.3 Although megakaryocytes can synthesise FV,4 platelet FV originates from 
secondary endocytosis of plasma FV.5-7 
FV deficiency8-10 is a rare bleeding disorder inherited as an autosomal recessive trait and 
associated with mutations in the F5 gene. Homozygous and doubly heterozygous individuals 
present with a strikingly variable bleeding tendency,11 which is mainly determined by their 
residual platelet FV.12-14 Since no FV concentrate or recombinant FV preparation is 
available, replacement therapy still relies on the administration of fresh-frozen plasma or 
platelet concentrates, with all well-known associated risks (volume overload, transmission of 
infectious agents, immune reactions and transfusion-related acute lung injury). 
At least 10% of all F5 mutations are splicing defects,15 i.e. they disrupt the process by which 
introns are removed from the primary transcript and exons are joined together to form the 
mature mRNA. The resulting mature transcript often contains a premature stop codon and is 
rapidly degraded. Accordingly, F5 splicing mutations are usually associated with severe 
bleeding symptoms.14,16-21 Several studies on various genetic disorders have shown that 
splicing defects are amenable to “RNA therapy” with antisense molecules specifically 
designed to anneal to the mutant pre-mRNA (without triggering its degradation) and to direct 
its maturation into the correct transcript (reviewed in refs.22-25). In particular, mutations that 
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disrupt an existing donor splice site can be corrected with U1 small nuclear RNA (snRNA) 
specifically modified to recognise the mutated splice site,26 whereas mutations that create a 
new splice site can be targeted with short antisense oligonucleotides or snRNAs that mask 
the aberrant splice site and prevent its interaction with the spliceosome. A growing body of 
in vitro and ex vivo evidence supports the efficacy and safety of antisense-based RNA 
therapy in several genetic diseases,23,24,27 but only few studies have been conducted in 
bleeding disorders.28-30 
The aim of the present study was to design and validate a personalised antisense-based RNA 
therapy for a previously described patient with severe FV deficiency (undetectable FV in 
both plasma and platelets),14 who recently suffered from a second spontaneous intracranial 
haemorrhage. The patient is homozygous for a deep-intronic splicing mutation (F5 
c.1296+268A>G) activating a cryptic donor splice site in intron 8 and causing the inclusion 
of a pseudo-exon with an in-frame stop codon in the mature transcript.14 The efficacy and 
cytotoxicity of two different antisense molecules targeting this mutation were tested in an in 
vitro model and ex vivo on patient-derived megakaryocytes. 
 
Materials and Methods 
 
Antisense molecules 
Morpholino oligonucleotide (MO). MOs are uncharged analogues of nucleic acids with a 
phosphorodiamidate backbone. Two 25-mer MOs were purchased from GeneTools 
(Philomath, OR, USA), one (rescuer) with a sequence complementary to the mutant F5 pre-
mRNA (5’-GGTCACATGGTATCTACTTACCTGT-3’, mutation site underlined) and the 
other (control) with an irrelevant sequence (5’-CCTCTTACCTCAGTTACAATTTATA-3’). 
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Engineered U7snRNA. U7snRNAs are a class of snRNAs involved in the 3’-end processing 
of histone pre-mRNAs.31 The U7-SmOPT construct32 (kindly provided by Dr. D. 
Schümperli, Bern, Switzerland) consists of a murine U7snRNA gene (including its natural 
promoter and 3’ sequences) cloned in the pSP64 vector. This construct expresses a 62-nt 
U7snRNA in which the U7-specific Sm-binding site has been replaced by the Sm-binding 
site (SmOPT) found in spliceosomal snRNAs. Using a mutagenic primer, we replaced the 
anti-histone pre-mRNA sequence with a sequence complementary to the aberrant splice site 
in the mutant F5 pre-mRNA (5’-TCTACTTACCTGTGGCTTTA-3’, mutation site 
underlined). The ability of this engineered anti-F5 U7snRNA (rescuer) to correct splicing of 
the mutant F5 pre-mRNA was compared to that of the original anti-histone U7snRNA 
(control). 
 
In vitro model: COS-1 or HepG2 cells transfected with F5 minigene constructs 
Cloning of the F5 minigene. A 2572-bp genomic fragment spanning F5 intron 7 through 
intron 9 and containing the c.1296+268A>G mutation was amplified from the patient’s 
genomic DNA using the PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, 
Amstelveen, The Netherlands) and cloned in the pTB expression vector33 between the 
unique Sac II and Nde I restriction sites (Figure 1). This mutant minigene construct was used 
as a template to obtain the corresponding wild-type construct by site-directed mutagenesis 
(QuikChange II XL Site-Directed Mutagenesis Kit, Agilent Technologies). The sequences of 
both F5 minigenes were checked by direct sequencing. 
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Figure 1. F5 minigene construct. 
Top: Schematic representation of the F5 minigene construct. The pTB vector contains the promoter 
(black arrow) and exons 1-3 of the human α-globin gene (grey boxes) as well as exons 24-25 of the 
fibronectin-1 gene (black boxes). High transcription levels are ensured by an SV40 enhancer (not 
shown). The F5 minigene, encompassing the 3’ end of intron 7, exon 8, intron 8 (with or without the 
+268A>G mutation), exon 9 and the 5’ end of intron 9 of the F5 gene, was inserted between the 
vector’s unique Sac II and Nde I restriction sites. The position of the c.1296+268A>G mutation is 
marked by a star. The dotted box indicates the intronic pseudo-exon (ψ). Bottom: Mature transcripts 
produced by the F5 minigene construct. The black arrows represent the primers used for qualitative 
analysis of the F5 mRNA; the white arrows represent the specific forward primers used to distinguish 
between the two differently spliced transcripts using real-time qPCR. 
 
 
Transfection of COS-1 and HepG2 cells. COS-1 and HepG2 cells were cultured in a 
humidified incubator at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM, Lonza, Verviers, Belgium) supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin. For each experiment, 80% 
confluent cells were seeded in a 6-well plate. After 24 hours, cells were switched to serum-
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free OptiMEM (GIBCO, Invitrogen, Bleiswijk, The Netherlands) and transiently transfected 
with the wild-type or mutant F5 minigene construct using Lipofectamine2000 (Invitrogen). 
Treatment with antisense molecules. Cells were treated with a single dose of antisense 
molecule (MO or U7-SmOPT construct) administered at the time of transfection with the F5 
minigene construct. MOs (1-10 μM) were delivered using EndoPorter Reagent (GeneTools, 
6 μM) in aqueous formulation. The U7-SmOPT constructs (0.25-2 μg, corresponding to a 
0.6-4.8u molar excess over the F5 minigene construct) were delivered by co-transfection 
with the F5 minigene using Lipofectamine2000 (Invitrogen). After 48 hours cells were 
harvested for mRNA analysis. 
Qualitative mRNA analysis. Total RNA was isolated using TRIzol reagent (Invitrogen) and 
quantified spectrophotometrically. Total RNA (2 μg) was reverse-transcribed for 2 hours at 
37 °C with MultiScribeTM reverse-transcriptase and random primers (Applied Biosystems, 
Bleiswijk, The Netherlands). The mRNA (cDNA) transcribed from the F5 minigene 
construct was amplified using a forward primer located in F5 exon 8 and a reverse primer 
located in the distal fibronectin exon of the pTB vector (Figure 1, black arrows). This primer 
pair amplifies exclusively the F5 minigene mRNA (and not any endogenous F5 mRNA) and 
yields products of different sizes according to the absence (283 bp) or presence (394 bp) of 
the F5 pseudo-exon in the mature transcript. PCR products were analysed by agarose gel 
electrophoresis and direct sequencing. 
Quantification of the normal and aberrant F5 transcripts. The normal and aberrant F5 
transcripts were quantified by real-time qPCR on a LightCycler 480 Real-Time PCR 
instrument (Roche Applied Science, Almere, The Netherlands). Two different forward 
primers, located at the exon 8-9 junction (5’-TCAGAGACACACTCAAAATCG-3’) and in 
the pseudo-exon (5’-AGTAATACAAAGGATCTGAGAC-3’), respectively (Figure 1, white 
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arrows), and a common reverse primer in the distal fibronectin exon of the pTB vector, were 
used in separate reactions to specifically amplify the normal (reference) and aberrant (target) 
F5 transcripts derived from the F5 minigene construct. Amplification reactions were carried 
out in a volume of 10 μL, including 100 ng total cDNA, 5 μL LightCycler 480 SYBR Green 
I Master mix (Roche) and 0.4 μM of each primer. An initial denaturation step (10 min at 95 
°C) was followed by 40 cycles of amplification (denaturation: 20 sec at 95 °C, annealing: 20 
sec at 57 °C, extension: 30 sec at 72 °C). The specificity of amplification products was 
checked by melting curve analysis (42-95 °C). Fluorescence curves were analysed with the 
LightCycler 480 Software version 1.5 and relative quantification was performed with the 2-
∆∆Ct method. All samples were assayed in duplicate. 
 
Cytotoxicity assays 
Potential cytotoxic effects of the antisense molecules and/or delivery agents were evaluated 
with the xCELLigence System (Roche). Details are reported in the Supplemental Data file. 
 
Ex vivo model: patient’s ex-vivo differentiated megakaryocytes 
Isolation and differentiation of circulating progenitor cells. The study was approved by the 
Ethical Committee of Padua Academic Hospital and conducted according to the Declaration 
of Helsinki. After obtaining informed consent, venous blood was drawn from the FV-
deficient patient and from a normal control in 0.129 M trisodium citrate. Megakaryocytes 
were differentiated from circulating haematopoietic progenitor cells as previously 
described.34 Briefly, mononuclear cells were isolated by centrifugation on Histopaque-1077 
(Sigma-Aldrich, Milan, Italy) density gradient, resuspended in serum-free Iscove’s modified 
Dulbecco’s medium (Celbio, Milan, Italy) and seeded in 24-well plates containing a glass 
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coverslip at the bottom of each well. Cells were cultured at 37 °C and 5% CO2 in medium 
supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin 
(Invitrogen) and 1% insulin-transferrin-selenium (Invitrogen), as well as 50 ng/mL 
thrombopoietin (TPO, Peprotech, London, UK) and 10 ng/mL interleukin-3 (IL-3, 
Peprotech) to induce differentiation towards the megakaryocytic lineage. 
Treatment with antisense molecules. At day 9 of culture, part of the cells were treated with 
rescuer MO (2.5 μM or 5.0 μM) or rescuer U7snRNA construct (200 ng or 400 ng), as 
described above. After 24 hours, glass coverslips were retrieved and processed for FV 
immunostaining. Untreated and treated cells from other wells were collected in TRIzol 
reagent (Invitrogen, 200 μL/well) for F5 mRNA analysis. 
F5 mRNA analysis. Total RNA isolation, reverse transcription and quantification of F5 
transcripts by real-time qPCR were carried out as described above, except for the use of a 
different reverse primer (located in F5 exon 10). 
FV immunostaining. Cells adhering to the glass coverslips were fixed with 2% 
paraformaldehyde and permeabilised with 0.5% Triton X-100. FV expression was visualised 
with a mouse monoclonal antibody directed against the human FV heavy chain (#5146, 
Hematologic Technologies, Essex Junction, VT, USA) and a FITC-labeled goat anti-mouse 
IgG secondary antibody (Chemicon International, Milan, Italy). Cell nuclei were stained 
with 1.5 μg/mL Hoechst 33258 (Sigma-Aldrich). Slides were examined with a Leica 
DMI6000CS fluorescence microscope (Leica Microsystems CMS, Wetzlar, Germany) using 
a 63x/1.40 oil immersion objective. Images were acquired by means of a DFC365FX camera 
and analysed with Leica LAS-AF 3.1.0 software. 
 
 
 
Chapter 6 
 104 
Results 
 
Splicing correction strategy 
The F5 c.1296+268A>G mutation introduces a strong donor splice site deep in intron 8, 
causing the inclusion of an intronic pseudo-exon with an in-frame stop codon in the mature 
F5 mRNA. In order to correct this aberrant splicing event, we designed antisense (“rescuer”) 
MO and engineered U7snRNA molecules targeting the mutation site, with the aim to induce 
pseudo-exon skipping. MO and U7snRNA molecules with irrelevant sequences were used as 
controls. 
 
In vitro model 
To develop an in vitro model to test the antisense molecules, we transiently transfected COS-
1 cells with a F5 minigene construct containing the c.1296+268A>G mutation (Figure 1) and 
analysed minigene mRNA by qualitative and real-time qPCR.  
The F5 minigene produced aberrantly spliced mRNA (containing the pseudo-exon) and 
correctly spliced mRNA (not containing the pseudo-exon) in a typical ratio of 5-10:1 (Figure 
2A, first two lanes). Treatment of transfected cells with 1-10 μM rescuer MO caused a dose-
dependent decrease in the aberrant transcript and a parallel increase in the normal transcript, 
indicating progressive correction of F5 pre-mRNA splicing (Figure 2A). The ratio between 
aberrant and normal mRNA decreased from 9.50 in untreated cells to 0.09 in cells treated 
with 10 μM rescuer MO, corresponding to a relative enrichment in the normal mRNA of 103 
times. To verify whether the effect of rescuer MO on F5 pre-mRNA splicing was specific, 
we performed additional transfection experiments to compare rescuer and control MO 
(Figure 2B). Treatment of transfected cells with 5 μM rescuer MO caused most of the F5 
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minigene pre-mRNA to be spliced correctly, whereas the same concentration of control MO 
was ineffective. The ratio between aberrant and normal mRNA decreased from 4.42 in 
untreated cells to 0.16 in cells treated with rescuer MO (correction factor 28-fold), whereas it 
hardly changed in cells treated with control MO (ratio 6.08, correction factor 0.7-fold). 
Finally, when COS-1 cells were transfected with the wild-type F5 minigene construct, not 
carrying the c.1296+268A>G mutation, only the correctly spliced mRNA was expressed and 
the administration of either rescuer or control MO did not affect its expression or splicing 
pattern (Figure 2B). 
Similar experiments were carried out with the U7-SmOPT constructs. When COS-1 cells 
were co-transfected with the mutant F5 minigene construct and increasing amounts of 
rescuer U7snRNA construct (0.25-2 μg, corresponding to a 0.6-4.8u molar excess over the 
F5 minigene construct), a dose-dependent decrease in the aberrant transcript and a parallel 
increase in the normal transcript were observed (Figure 2C). The ratio between the aberrant 
and normal F5 mRNA decreased from 12.07 in untreated cells to 0.14 in cells treated with 2 
μg rescuer U7snRNA construct, indicating progressive correction of pre-mRNA splicing up 
to a correction factor of 84-fold. The ability of rescuer U7snRNA to specifically restore 
normal splicing of the F5 minigene transcript was confirmed in independent transfections 
(Figure 2D), where the rescuer U7snRNA construct (2 μg) decreased the ratio between 
aberrant and normal F5 mRNA from 2.89 in untreated cells to 0.03 (correction factor 106-
fold), whereas the control U7snRNA construct showed no corrective potential (3.44, 
correction factor 0.8-fold). No effect of rescuer or control U7snRNAs was observed in COS-
1 cells transfected with the wild-type F5 minigene construct. 
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Figure 2. Splicing correction in COS-1 cells. 
Panels A-B: COS-1 cells were transfected with the mutant or wild-type F5 minigene construct and 
either left untreated (Untr.) or treated with the indicated concentrations of rescuer MO (R-MO) or 
control MO (C-MO). Panels C-D: COS-1 cells were transfected with the mutant or wild-type F5 
minigene construct and either left untreated (Untr.) or co-transfected with the indicated amounts of 
the U7-SmOPT construct expressing anti-F5 (rescuer) U7snRNA (R-U7) or control U7snRNA (C-
U7). 2 μg U7-SmOPT construct corresponds to a molar excess of 4.8u over the F5 minigene 
construct. After 48 hours RNA was isolated, reverse-transcribed and analysed by PCR and gel 
electrophoresis. Representative gels are shown. M, 100 bp marker. 
 
 
Since the liver is the physiological site of FV production in vivo, the ability of rescuer MO 
and U7snRNA to correct splicing of the mutant F5 pre-mRNA was also tested in HepG2 
cells. These cells were transfected with the mutant F5 minigene construct and either left 
untreated or treated with 5 μM rescuer MO or 2 μg of the rescuer U7snRNA construct 
(Figure 3A). The ratio between aberrant and normal mRNA was 6.44±1.64 (mean ± standard 
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deviation of 4 replicate transfections) in untreated cells and decreased to 0.20±0.03 in cells 
treated with rescuer MO (correction factor 32-fold, p=0.005) and to 0.034±0.003 in cells 
treated with rescuer U7snRNA (correction factor 189-fold, p=0.004) (Figure 3B), similar to 
what observed in COS-1 cells. In a control experiment, control MO and U7snRNA with 
irrelevant sequences did not affect F5 pre-mRNA splicing (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Splicing correction in HepG2 cells. 
HepG2 cells were transfected with the mutant F5 minigene construct and either left untreated (Untr.) 
or treated with 5 μM rescuer MO (R-MO) or co-transfected with 2 μg of the U7-SmOPT construct 
expressing anti-F5 (rescuer) U7snRNA (R-U7). 2 μg U7-SmOPT construct corresponds to a molar 
excess of 4.8u over the F5 minigene construct. After 48 hours RNA was isolated, reverse-transcribed 
and analysed by PCR and gel electrophoresis (A) and real-time qPCR (B). The gel shows the effects 
of 5 μM R-MO and 2 μg of rescuer U7snRNA construct on F5 pre-mRNA splicing in HepG2 cells 
transfected with the mutant F5 minigene (quadruplicate transfections). M, 100 bp marker. Results of 
the quantification experiments are expressed as the ratio between the aberrant and normal F5 mRNA, 
plotted on a logarithmic scale. The quantification data represent the mean r standard deviation of the 
four replicates. 
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Treatment with rescuer or control antisense molecules affected the viability and/or 
proliferation of COS-1 cells and (to a much lesser extent) HepG2 cells (Supplemental Data 
file). 
 
Ex vivo model 
Haematopoietic progenitor cells from the FV-deficient patient and a normal control were 
cultured in serum-free medium in the presence of TPO and IL-3 to induce differentiation 
towards the megakaryocytic lineage. While control cells rapidly developed into FV-
expressing megakaryocytes (Figure 4F), the patient’s cells did not show any sign of FV 
expression even after 9 days of culture (Figure 4A). However, treatment with rescuer MO 
(2.5-5.0 μM) or rescuer U7snRNA construct (200 ng and 400 ng) effectively restored FV 
expression in the patient’s cells (~80% positivity, Figure 4B-E). Although this technique 
does not lend itself well to quantitative evaluation, green fluorescence was more intense 
(suggesting higher FV expression) in patient’s megakaryocytes treated with U7snRNA than 
in those treated with MO, whereas no clear-cut correlation with the intensity of treatment 
was noticed. Moreover, also in this model, administration of antisense molecules was 
associated with significant cytotoxicity, as demonstrated by the marked reduction in the 
number of viable cells following treatment. 
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Figure 4. Ex vivo splicing correction in patient’s megakaryocytes. 
Haematopoietic progenitor cells were isolated from peripheral blood and differentiated towards the 
megakaryocytic lineage as described under Methods. At day 9 of culture, the FV-deficient patient’s 
cells were either left untreated (A) or treated with rescuer MO (R-MO) or with the U7-SmOPT 
construct expressing rescuer U7snRNA (R-U7) at the indicated concentrations (B-E). Untreated cells 
from a normal control are shown for comparison (F). After immunofluorescence staining with 
Hoechst 33258 (cell nuclei, in blue) and with a FITC-labelled anti-mouse antibody recognising the 
primary anti-FV antibody (FV, in green), cells were examined under a Leica DMI6000CS 
fluorescence microscope using a 63x/1.40 oil immersion objective at room temperature. Images were 
acquired using a DFC365FX camera and analysed with Leica LAS-AF 3.1.0 software. Each panel 
represents the overlay of two images of the same preparation stained with Hoechst 33258 and FITC-
labelled antibody, respectively. Four representative microscope fields are shown for each condition. 
 
For a more quantitative assessment of the efficacy of antisense molecules in patient’s 
megakaryocytes, total RNA was isolated from untreated and treated megakaryocytes and F5 
mRNA was analysed by real-time qPCR (Figure 5). The ratio between aberrant and normal 
F5 transcripts in untreated megakaryocytes (158.3) was similar to that observed in the 
patient’s platelets (194.8, unpublished observation) and indicated that <1% of F5 mRNA is 
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spliced correctly in this patient. Treatment with rescuer MO and rescuer U7snRNA construct 
corrected the splicing pattern by 2-3 orders of magnitude in a roughly dose-dependent 
manner. At the concentrations used, rescuer U7snRNA was somewhat more effective than 
rescuer MO in restoring normal splicing, in line with the protein expression data (and with 
the in vitro splicing correction experiments). 
 
 
 
 
 
 
 
 
Figure 5. Ex vivo splicing correction in patient’s megakaryocytes. 
Haematopoietic progenitor cells were isolated from peripheral blood and differentiated towards the 
megakaryocytic lineage as described under Methods. At day 9 of culture, the FV-deficient patient’s 
cells were either left untreated or treated with rescuer MO (R-MO) or with the U7-SmOPT construct 
expressing rescuer U7snRNA (R-U7) at the indicated concentrations. Following isolation and 
reverse-transcription of total RNA, the F5 mRNA splicing pattern in untreated and treated patient’s 
megakaryocytes was analysed by real-time qPCR. Results are expressed as the ratio between the 
aberrant and normal F5 mRNA, plotted on a logarithmic scale. 
 
 
Discussion 
Antisense-based RNA therapy is rapidly emerging as a promising tool to correct splicing 
defects.22-24,27 Unlike classical gene therapy, where a functional copy of the defective gene 
(cDNA) under control of a strong promoter is introduced in the patient’s cells, RNA therapy 
relies on short mutation-specific antisense oligonucleotides or engineered snRNAs that 
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anneal to the mutant primary transcript and re-direct its maturation into the correct mRNA. 
By acting at the RNA rather than DNA level, this form of molecular therapy does not affect 
the transcriptional regulation of the targeted gene (or any other gene). 
Despite the encouraging results obtained in several genetic diseases, the potential utility of 
RNA therapy in coagulation disorders is only just beginning to be explored.25 Among all 
coagulation factor deficiencies, FV deficiency represents a particularly suitable target for 
RNA therapy, because: a) no FV concentrate or recombinant FV preparation is available for 
substitutive therapy; b) the FV requirement for adequate haemostasis is extremely low, 
making a few % FV sufficient to prevent life-threatening bleeding;19,35-37 and c) the large 
size of the F5 cDNA makes conventional gene therapy particularly challenging. Here we 
present the first application of RNA therapy to severe FV deficiency and we provide in vitro 
and ex vivo evidence that mutation-specific antisense molecules can effectively rescue a F5 
splicing mutation. 
The mutation that we have targeted (F5 c.1296+268A>G) activates a cryptic donor splice 
site deep in intron 8, causing the retention of an intronic pseudo-exon in the mature 
mRNA.14 Although this is presently the only known F5 splicing defect that can be corrected 
through MO- or U7snRNA-mediated pseudo-exon skipping, deep-intronic splicing 
mutations may be more prevalent than previously suspected.38 In fact, deep-intronic splicing 
mutations potentially amenable to this corrective approach have been identified in the F8,39-
42 FGB30 and FGG43 genes. 
COS-1 and HepG2 cells transfected with a F5 minigene construct containing the 
c.1296+268A>G mutation provided a suitable in vitro model to test the antisense molecules, 
even if the relative proportion of correctly spliced mRNA was much higher in this model 
(10-20%) than in the patient’s platelets (~0.5%, as estimated by real-time qPCR). This is not 
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surprising considering that: a) the splicing pattern/efficiency is known to vary in different 
cell types; b) the minigene transcript is different from the full-length F5 transcript, which 
may affect the susceptibility of the aberrantly spliced mRNA to nonsense-mediated decay; 
and c) the transcript ratio in the minigene model also varied according to cell status and 
transfection conditions (data not shown). However, treatment of transfected cells with 
mutation-specific antisense molecules restored normal splicing in a specific and dose-
dependent manner. In particular, the highest concentrations of antisense MO and U7snRNA 
increased the relative proportion of the correctly spliced mRNA by 1-2 orders of magnitude. 
Similar correction efficiencies, if achieved in vivo, would be more than sufficient to bring the 
patient’s FV level in the safe range. 
The F5 c.1296+268A>G mutation was originally identified in the homozygous state in a 
patient with undetectable FV and a life-threatening bleeding diathesis.14 To prove that our 
antisense MO and U7snRNA could rescue the patient’s FV deficiency, we showed that they 
could effectively correct the F5 mRNA splicing pattern and restore FV expression in the 
patient’s ex vivo differentiated megakaryocytes. Although megakaryocytes are not the 
physiological site of FV production in vivo,5-7 they have been shown to synthesise FV in 
culture,4 offering us the opportunity to test the antisense molecules on the patient’s own cells 
without a liver biopsy. Unfortunately, the antisense molecules could not be tested directly on 
the patient’s hepatocytes, but their efficacy in correcting the splicing defect in HepG2 cells 
transfected with the mutant F5 minigene construct suggests that they would be able to 
restore FV expression in the patient’s hepatocytes as well, especially considering the fact 
that the liver is a preferential site of accumulation of systemically injected MOs.44,45 
Treatment with rescuer (and control) MO and U7snRNA molecules adversely affected the 
viability and/or proliferation of COS-1 and (to a much lesser extent) HepG2 cells in in vitro 
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cytotoxicity assays. However, toxic effects were largely attributable to the transfection 
reagents used to deliver the antisense molecules rather than to the antisense molecules 
themselves. Since the delivery of antisense molecules to target cells in vivo does not rely on 
transfection reagents, but rather on free uptake by body cells (MOs)46 or on targeted delivery 
using engineered viral vectors (U7snRNAs),47 major adverse effects in treated patients 
appear unlikely. In fact, antisense molecules have shown excellent safety profiles in several 
in vivo studies of other genetic diseases, both in animal models and in human volunteers, 
being well tolerated even after systemic administration.44,47 Nevertheless, since each 
antisense molecule has a unique sequence, off-target effects can never be excluded. 
In summary, our data show that specific antisense molecules targeting the c.1296+268A>G 
mutation can correct splicing of the mutant F5 pre-mRNA in vitro and restore FV synthesis 
in the patient’s megakaryocytes ex vivo. These findings provide proof-of-principle for the 
efficacy of RNA therapy for this particular F5 gene mutation and support RNA therapy as a 
possible alternative to substitutive therapy with blood derivatives in severe FV deficiency. 
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Supplemental material 
 
Cytotoxicity assays 
 
Methods 
Potential cytotoxicity of the antisense molecules and/or delivery agents was evaluated with 
the xCELLigence System (Roche), which uses impedance measurements for real-time 
monitoring of cell behaviour.1 Subconfluent COS-1 and HepG2 cells were seeded in an E-
plate 96 and the impedance of the cell layer (cell index) was recorded every hour for 5 days. 
The plate was kept at 37 °C and 5% CO2 throughout the experiment. Based on control 
experiments, cells were seeded at a density of 5000 cells/well (COS-1) or 7500 cells/well 
(HepG2) and allowed to adhere and grow for 24 hours before treatment with 5 μM MO (and 
6 μM EndoPorter Reagent) or 2 μg U7-SmOPT construct (and 0.5 μL Lipofectamine) or the 
delivery agents alone. During the first 2 days after treatment, impedance was recorded every 
15 minutes to closely monitor cell viability and proliferation. All measurements were done in 
triplicate. Wells containing medium without cells were used as a blank. Data were analysed 
with the RTCA Software 1.2 (Roche). 
Cell viability 24 hours post-treatment with antisense molecules and/or delivery agents was 
also assessed with the MTT assay (Sigma-Aldrich), which was carried out in 8-plo according 
to the manufacturer’s instructions. 
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Results 
To test whether the antisense molecules or the reagents used to deliver them to the cells 
cause any cytotoxicity, we monitored the proliferation of COS-1 and HepG2 cells in the 
absence and presence of treatment using xCELLigence technology (Supplemental Figure). 
Untreated COS-1 cells grew steadily and reached a cell index of ~2.5 after five days. 
Treatment with rescuer or control MO caused an initial decrease in the cell index, indicative 
of cell stress, but after two days cells started to recover and resumed proliferation 
(Supplemental Figure, panel A). Interestingly, administration of EndoPorter Reagent alone 
had exactly the same effect (Supplemental Figure, panel A), suggesting that the toxicity of 
MO treatment is attributable to the delivery agent rather than to the antisense molecules 
themselves. Treatment of COS-1 cells with rescuer or control U7snRNA constructs was also 
associated with transient toxicity, but this effect was only partially mediated by the 
transfection agent (Lipofectamine) used to deliver the constructs to the cells (Supplemental 
Figure, panel B). 
Untreated HepG2 cells grew steadily reaching a plateau at a cell index of ~3.3 
(Supplemental Figure, panel C). Treatment with rescuer or control MO seemed to enhance 
rather than decrease their proliferation (Supplemental Figure, panel C), whereas treatment 
with rescuer or control U7snRNA constructs had only a minor adverse effect on the cell 
index (Supplemental Figure, panel D), suggesting that HepG2 cells are less sensitive than 
COS-1 cells to cytotoxicity induced by the antisense molecules and/or their respective 
delivery agents. 
Essentially the same results were obtained when cell viability was assessed using the MTT 
assay (data not shown). 
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Supplemental figure. Cytotoxicity assays. 
COS-1 (A, B) and HepG2 (C, D) cells were seeded in the wells of an E-plate 96 and allowed to 
adhere and grow at 37 °C for 24 hours before treatment with the indicated antisense molecules and/or 
delivery agents (EP, EndoPorter Reagent; R-MO, rescuer MO; C-MO, control MO; Lipo, 
Lipofectamine; R-U7, U7-SmOPT construct expressing rescuer U7snRNA; C-U7, U7-SmOPT 
construct expressing control U7snRNA). The cell index, reflecting cell adhesion, growth and 
proliferation, was monitored continuously for a total of 5 days with xCELLigence technology. Each 
condition was tested in triplicate and average cell index tracings are shown. The “spikes” in the 
signal at 24 and 48 hours are due to the removal of the plate from the incubator to administer the 
treatment (at 24 hours) and to refresh the medium (at 48 hours). 
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Coagulation factor V (FV) deficiency1-4 is a rare autosomal recessive bleeding disorder 
caused by F5 gene mutations that impair FV protein synthesis and/or function. Affected 
patients experience a heterogeneous bleeding diathesis which is only weakly correlated with 
plasma FV levels. In patients with undetectable plasma FV, symptoms range from mild 
bleeding episodes (easy bruising, epistaxis, gum bleeding and menorrhagia) to life-
threatening intracranial or gastrointestinal hemorrhages.5 Although a FV concentrate is under 
development,6 administration of fresh frozen plasma (and/or platelet concentrates) is 
presently the only option for the prevention and treatment of bleeding episodes in these 
patients.7 This form of therapy is however not optimal, especially in case of long-term 
treatment or life-long prophylaxis, because regular plasma transfusions are associated with 
several risks and complications (volume overload, transmission of infectious agents, allergic 
reactions, transfusion-related acute lung injury).8 
In clinical laboratories the diagnosis of FV deficiency relies entirely on clotting tests and on 
the measurement of FV levels in plasma. F5 mutation screening is rarely performed, because 
it requires a specialized molecular genetic facility, it is expensive and labor-intensive, and it 
does not influence treatment decisions. However, identification of the responsible 
mutation(s) is the only way to definitely prove the genetic nature of FV deficiency in a 
patient and to firmly establish the carrier status in his/her family members. In turn, this 
information may be used for genetic counseling of affected individuals (especially in 
countries where consanguineous marriages are common) and for prenatal diagnosis of the 
most severe forms.9 Moreover, the molecular diagnosis opens the possibility for the 
development of personalized therapeutic strategies based on molecular approaches, such as 
the correction of splicing defects using antisense molecules10-13 or the read-through of 
nonsense mutations using aminoglycosydes.14,15 
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Conventional mutation screening techniques, based on the amplification and sequencing of 
each individual exon of the F5 gene, identify both mutations in a large proportion of FV-
deficient patients, but still leave 10-20% of cases genetically unsolved. Mutations may be 
overlooked either because they reside in regions of the gene that are not routinely screened 
(promoter region, introns, 3’-UTR) or because they are not detectable by amplification and 
sequencing of individual exons (large deletions and duplications involving multiple exons). 
In other cases mutations are identified, but their deleterious effects on gene expression are 
not recognized. This is typically the case for exonic splicing mutations, which are often 
mistaken for rare synonymous or benign-missense polymorphisms. Unraveling these 
mutations “in disguise”16 is not only necessary for a correct molecular diagnosis of the 
disease, but can also point out new mechanisms of regulation of gene expression. 
 
Specific contributions of this thesis 
The work described in this thesis has addressed the molecular genetics of FV deficiency as a 
starting point for the development of personalized approaches of molecular therapy, leading 
to the following original contributions: 
1) Development and validation of a F5 MLPA assay for the efficient and cost-effective 
detection of large deletions or duplications of the F5 gene (Chapter 3); 
2) Broadening of the F5 mutational spectrum by six novel mutations, including a large 
deletion and two splicing mutations “in disguise” (Chapters 3-7); 
3) Proof-of-principle of antisense-based correction of two different F5 splicing defects 
(Chapters 5 and 6); 
4) Evidence for the role of plasma full-length TFPI as a phenotype modulator and a possible 
therapeutic target in FV deficiency (Chapter 7). 
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Development and validation of a F5 MLPA assay 
Structural variation, including copy number variations (i.e. deletions, duplications and 
insertions) as well as translocations and inversions of larger (>1 kb) genomic fragments, has 
been recognized as a common feature of the human genome and a major cause of genetic 
disease.17,18 However, the role of copy number variations in the pathogenesis of FV 
deficiency has remained largely unexplored, mainly due to the lack of suitable tools to 
identify these genetic defects in the F5 gene. In fact, of the two F5 large deletions identified 
so far, the first has been discovered more or less by chance as part of a major cytogenetic 
defect (interstitial deletion of the long arm of chromosome 1) responsible for the patient’s 
mental retardation,19 while the other was initially suspected on the basis of the patient’s 
apparent homozygosity (actual hemizygosity) for all SNPs located in the 5’ portion of the 
gene and subsequently mapped through a laborious long-range PCR approach.20 
To overcome these difficulties, we have now developed an in-house multiplex ligation-
dependent probe amplification (MLPA) assay for the efficient detection of large deletions 
and duplications of F5 gene exons (Chapter 3). This assay makes use of specific probes 
which, once hybridized to their target (F5) and reference (other genes) sequences on the 
patient’s genomic DNA and ligated, can be amplified with a single primer pair, allowing the 
relative quantification of multiple F5 gene regions within a single PCR reaction.21,22 Due to 
the large size of the F5 gene (80 kb, 25 exons) and to the numerous (sequence, length and 
melting temperature) requirements that MLPA probes must fulfill,23 probe design was 
technically quite challenging. First of all, we could not accommodate all F5-specific probes 
in a single MLPA reaction, but we had to divide the probes in two sets, requiring two 
separate MLPA reactions to cover the whole gene. Secondly, we were unable to design 
suitable probes for exons 5, 8, 12, 20, 23 and 25, and had to place the probes for exons 2 and 
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3 in the adjacent intronic regions (intron 2 and 3). In order to achieve an adequate coverage 
of the whole F5 locus, we included two different probes for the large exon 13, as well as 
probes for sequences located upstream and downstream of the F5 gene. This resulted in a 
total of 22 F5-specific probes evenly distributed throughout the gene. When tried out on 
control DNA samples, all probes yielded specific and reproducible peaks of the expected 
size, except for the shortest probe of each set, which produced very low peaks and 
occasional double peaks, possibly due to aspecific binding to partially homologous target 
sequences elsewhere in the genome. These probes definitely require further optimisation. 
However, the ability of our in-house F5 MLPA assay to unequivocally detect and define a 
previously described large deletion20 makes it a reliable method to screen for the presence of 
F5 large deletions or duplications in patients’ samples. Due to its relative simplicity of 
execution, this assay can be performed in any molecular genetics laboratory, providing an 
efficient and cost-effective tool for the rapid detection of F5 copy number variations in FV-
deficient patients. 
Application of our in-house F5 MLPA assay to 14 genetically unresolved patients with 
partial or severe FV deficiency identified a novel large deletion involving F5 exons 9-10, 
which was subsequently confirmed by digital PCR (dPCR) and fine-mapped by long-range 
PCR and direct sequencing (Chapter 3). Despite this encouraging result, we had expected to 
find more F5 copy number variations in this selected population of FV-deficient patients, 
where conventional F5 mutation screening methods had already failed to identify one or 
both mutations. However, the genetic nature of the FV deficiency had not been confirmed in 
all patients by family studies, and the alternative diagnosis of combined FV and FVIII 
deficiency24 had not always been excluded in the patients with partial deficiency. Moreover, 
we may have missed single-exon deletions/duplications of the few exons not covered by our 
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probes or of the regions (promoter, exon 1) whose probes do not yield optimal peaks in our 
MLPA assay. Alternatively, it is possible that large deletions/duplications are a truly rare 
cause of FV deficiency. In fact, a sequence analysis conducted using the RepeatMasker 
software (www.repeatmasker.org) showed that repeated elements that often mediate gross 
gene rearrangements25 are less represented in the F5 gene than in the homologous F8 gene 
(unpublished observation). This is the case for Alu sequences (making up 4.1% of the F5 
sequence vs. 7.9% of the F8 sequence), LINEs (23.8% vs. 44.2%) and particularly LTR 
elements (1.9% vs. 14.7%). 
The performance of MLPA assays is strongly dependent on pre-analytical variables, such as 
the DNA extraction method, the purity and quality of the DNA preparation and the 
composition of the buffer in which it is stored. Moreover, polymorphisms or mutations in the 
probe target sequences (especially if located close to the probe ligation site) can interfere 
with probe ligation, thereby giving rise to a false positive result, which may be interpreted as 
a single-exon deletion.26,27 Therefore, MLPA findings should always be confirmed with an 
independent method, typically long-range PCR and/or qPCR. In our study, we have used 
dPCR, a relatively new microfluidic technique which allows the sensitive detection and 
accurate quantification of even tiny amounts of template DNA.28,29 The extreme sensitivity 
of dPCR is achieved by partitioning a qPCR mix in a large number of wells (e.g. 20,000), 
each of which ends up containing only one or no template molecule, and by counting the 
number of wells in which amplification takes place. This trick makes dPCR able to resolve 
small differences in the number of copies of template DNA, such as those involved in 
heterozygous deletions or duplications of the target sequence, which are challenging to 
detect by conventional qPCR. Although dPCR finds most of its applications in oncology30,31 
and microbiology,32,33 its extreme sensitivity has also been successfully exploited in the 
 
General Discussion 
 143 
coagulation field for the non-invasive prenatal diagnosis of haemophilia A and B in maternal 
plasma DNA.34 
 
Broadening of the F5 mutational spectrum 
To date, 153 F5 gene mutations have been reported (Human Genome Mutation Database, 
accessed in March 2015), mostly missense and nonsense mutations. This thesis describes six 
novel F5 loss-of-function mutations, including a large deletion, two missense mutations and 
three splicing mutations (Table 1). 
 
Table 1. Novel F5 mutations described in this thesis 
Mutation type Mutation* Molecular mechanism Chapter 
Large deletion Deletion extends 
from IVS8+1311 to 
IVS10+378  
1.8-kb deletion including exons 9-10 3 
Missense 668G>C 
(Cys165Ser) 
Loss of a highly conserved disulfide bridge 
in the A1 domain 
5 
 1918T>G 
(Trp582Gly) 
Replacement of a highly conserved residue 
in the A2 domain 
7 
Splicing IVS3+2T>C Classical splicing mutation disrupting the 
donor splice site of intron 3 
4 
 1371C>G 
 
Apparently synonymous exonic mutation 
impairing pre-mRNA splicing by activating 
a cryptic donor splice site in exon 8 
5 
 IVS8+268A>G Deep-intronic mutation activating an 
intronic pseudo-exon with an in-frame stop 
codon 
6 
*Annotated according to the classical nomenclature of Jenny et al.35 
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Large deletion 
The detection of F5 large deletions and their contribution to the F5 mutational spectrum has 
been discussed in the previous paragraph. 
 
Missense mutations 
The causal role of a missense mutation (amino acid substitution) is often difficult to prove 
without expressing the variant as a recombinant protein.36 However, causality may be 
inferred from the evolutionary conservation of the affected amino acid residue, an in silico 
analysis with prediction algorithms (e.g. SIFT or PolyPhen), structural data (if the three-
dimensional structure of the protein is available), co-segregation of the genetic variant with 
the phenotype and absence of the variant in the general population. 
Both F5 missense mutations described in this thesis affect highly conserved amino acid 
residues. The first (Cys165Ser, Chapter 5) abolishes a conserved disulfide bridge in the A1 
domain of FV and its causal role has been verified experimentally by in vitro expression of 
the recombinant mutant. The second (Trp582Gly, Chapter 7) replaces a bulky Trp located 
in the core of the A2 domain with a Gly and was predicted to be damaging by both SIFT and 
PolyPhen. In addition, this mutation showed complete co-segregation with FV levels in two 
(distantly related) families and was also found in a third (apparently unrelated) family with 
FV deficiency, all from the Sultanate of Oman. Screening of the Omani general population 
for this mutation might be warranted. 
 
Splicing mutations 
The complexity of the splicing code offers many chances for mutations to disrupt normal 
pre-mRNA splicing. Mutations can destroy functional donor and acceptor splice sites, 
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activate cryptic splice sites in exons or introns and weaken/strengthen auxiliary splicing 
signals (exonic and intronic splicing enhancers and silencers), thereby leading to aberrant 
splicing events such as exon skipping or intron retention in the mature mRNA.37 
Accordingly, it has been estimated that splicing mutations may represent up to 50% of all 
pathogenic DNA variants.38 
The under-representation of splicing mutations in the F5 mutational spectrum is likely due to 
the fact that current mutation screening strategies detect only splicing mutations affecting the 
canonical donor and acceptor splice sites, whereas splicing mutations acting via other 
mechanisms remain largely undetected or unrecognized.39 This thesis reports an example of 
a classical splicing mutation, abolishing the donor splice site of F5 intron 3 (Chapter 4), and 
two unconventional splicing mutations (Chapters 5 and 6), which were missed by the initial 
F5 mutation screening. 
The splicing defect associated with the F5 IVS3+2T>C mutation (Chapter 4) could 
unfortunately not be characterized in detail due to the lack of a patient’s blood sample 
suitable for RNA isolation and to the technical challenge of cloning a F5 minigene 
containing intron 3 (>11 kb). However, the most likely consequence of this mutation is exon 
3 skipping, as this aberrant splicing event also occurs physiologically,40 presumably because 
of the low consensus score of the acceptor splice site of intron 3 (0.75 according to the 
NNsplice software). 
The F5 1371C>G mutation (Chapter 5), located in exon 8, was detected by sequencing of 
the coding region, but its effect on splicing was not immediately recognized. As it is often 
the case for exonic variants, the mutation was only assessed on the basis of its impact on 
translation. Since it did not predict an amino acid change, it was interpreted as a (rare) 
neutral polymorphism. However, an in silico sequence analysis indicated that this variant 
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may activate a cryptic donor splice site potentially competing with the canonical donor 
splice. This was subsequently confirmed by analysis of the patient’s cDNA and by 
characterization of the isolated variant using a minigene model. Similar examples of 
apparently synonymous mutations affecting pre-mRNA splicing have been recently 
described in the LMAN1, VWF and F8 genes.41-43 In fact, evidence is accumulating that 
synonymous mutations can be pathogenic via several mechanisms,  not only by impairing 
correct pre-mRNA splicing,44 but also by affecting mRNA stability, translation rate and co-
translational folding of the nascent protein.45,46 In other words, synonymous mutations are 
not always neutral.47 This should be kept in mind when annotating and prioritizing exonic 
variants of unknown significance identified by next generation sequencing. 
The F5 IVS8+268A>G mutation (Chapter 6) is a typical deep-intronic mutation which 
activates a cryptic donor splice site in intron 8, resulting in the inclusion of an intronic 
pseudo-exon with an in-frame stop codon in the mature F5 mRNA. This mutation was only 
identified after finding a splicing aberration in the patient’s F5 cDNA.48  Its causative role 
was supported by splicing prediction software and experimentally proven by expression in a 
minigene model. Deep-intronic mutations activating intronic pseudo-exons are more 
common than previously suspected, and several examples have been described in various 
genes,49 including F8,50-53 FGB54 and FGG.55 However, deep-intronic mutations are still 
largely overlooked, because introns are usually not sequenced and cDNA analysis is rarely 
performed in patients. 
Overall, our findings underscore the importance of analyzing the patient’s cDNA in order to 
detect splicing defects. Unfortunately, cDNA analysis is not routinely performed, as 
extraction of RNA from blood cells requires an especially collected blood sample. Moreover, 
RNA processing and analysis are labor-intensive and generally more demanding than DNA 
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analysis. In the absence of cDNA analysis, evaluation of variants of unknown significance 
using splicing prediction software might help identify potential effects on splicing, at least 
those mediated by the creation or destruction of splice sites, whereas the ability of these 
algorithms to predict functional auxiliary splicing signals is still quite limited.43 Therefore, in 
silico predictions should be (ideally) always supported by experimental verification in 
minigene models. On the other hand, targeted resequencing of introns in genetically 
unsolved patients could lead to the identification of deep-intronic mutations potentially 
affecting splicing, as recently shown for hemophilia A patients in which no mutation was 
found by sequencing of the F8 coding sequence.50,51 
 
Two of the FV-deficient patients described in this thesis (Chapters 4 and 6), who were 
homozygous for splicing mutations, had a particularly severe bleeding phenotype, 
characterized by recurrent intracranial haemorrhages. A review of the literature shows that 
this is often the case for patients who are homozygous for F5 splicing mutations (Table 2). 
This is remarkable because intracranial hemorrhages are otherwise a rather rare (6%) 
manifestation of the disease, even in the subgroup of patients with undetectable FV, where 
the incidence is 12.5%.5 
The reason for the association between F5 splicing mutations and severe clinical phenotype 
is unclear, but may relate to the fact that splicing defects often result in grossly abnormal 
mRNA containing a premature stop codon, which triggers mRNA degradation by the 
nonsense-mediated decay (NMD) pathway.40,48,56 Even if the correct reading frame is 
preserved and the aberrantly spliced mRNA is not degraded, the encoded protein does not 
fold properly and usually fails to be secreted.57-59 
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Table 2. Characteristics of FV-deficient patients with homozygous F5 splicing mutations 
Patient characteristics FV:C Bleeding symptoms Mutation* Reference 
Omani female toddler 
Consanguineous parents 
<1% Multiple intracranial hemorrhages IVS3+2T>C 
(homozygous) 
This thesis 
(Chapter 4) 
Iranian female 
Consanguineous parents 
5% Epistaxis IVS8+6T>C 
(homozygous) 
Dall’Osso 
et al.40 
Italian male, 31 years old <1% Umbilical bleeding at birth 
Recurrent epistaxis 
Joint & muscle hematomas 
Hemothorax 
2x intracranial hemorrhage 
IVS8+268A>G 
(homozygous) 
Castoldi et 
al.48 
This thesis 
(Chapter 6) 
Chinese male, 37 years 
old 
1.6% Gum bleeding 
Hemorrhage after appendectomy 
Intracranial bleeding at 37 years  
IVS8-2A>G 
(homozygous) 
 Fu et al.60 
Female baby 
Parents distantly related 
<1% Umbilical bleeding at birth 
Gum bleeding 
Multiple intracranial hemorrhages 
IVS10-1G>T 
(homozygous) 
Schrijver et 
al.61  
Slovenian male <1% Gastro-intestinal bleeding 
Gum, joint and muscle bleeding 
Intracranial bleeding at 11 years 
IVS18-12T>A 
(homozygous) 
Lunghi et 
al.56 
Iranian male, 19 years 
old 
Consanguineous parents 
<1% Mouth and nose bleeding 
Repeated hemarthrosis 
Hematuria 
Bleeding after dental extractions 
IVS19+3A>T 
(homozygous) 
Asselta et 
al. 57 
*Annotated according to the classical nomenclature of Jenny et al.35 
 
Antisense-based RNA therapy of FV deficiency 
Recent advances in molecular biology techniques make it possible to correct splicing defects 
by means of specific antisense molecules that anneal to a target pre-mRNA and thereby 
influence splicing decisions.12,62,63 These antisense molecules include specifically modified 
U1 small nuclear RNA (U1snRNA), which can be used to recognize donor splice sites 
weakened by mutation, as well as synthetic antisense oligonucleotides and engineered 
U7snRNA, which can be employed to hide incorrect splicing signals introduced by mutation. 
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These approaches can also be fruitfully combined to maximize splicing correction.64 Efforts 
to develop, test and implement antisense-based RNA therapeutic strategies are presently 
ongoing for several genetic diseases,12,13,65-67 including coagulation disorders.62 
Severe FV deficiency would be a particularly suitable target for this form of molecular 
therapy, because current treatment (based on the administration of fresh frozen plasma) is 
not optimal, while gene therapy is hampered by the large size of the F5 cDNA. Moreover, a 
minimal increase in the FV levels would be already sufficient to turn the severe clinical 
phenotype often associated with F5 splicing mutations into a milder bleeding tendency.68 
Finally, the liver (i.e. the physiological site of FV synthesis in humans) represents a 
privileged target for antisense-based therapy, because systemically injected antisense 
oligonucleotides tend to accumulate in this organ,69 while engineered snRNAs can be 
specifically delivered to the liver using appropriate viral vectors.70,71 
In this thesis we present in vitro evidence for the efficacy of antisense molecules in 
correcting the effects of two different F5 splicing mutations associated with FV deficiency. 
In Chapter 5 we targeted the F5 1371C>G mutation, which activates a cryptic donor splice 
site in exon 8 and causes the in-frame deletion of the last 18 nucleotides of exon 8 from the 
mature mRNA. Using a minigene model in liver (HepG2) cells, we showed that a 
morpholino antisense oligonucleotide directed against this mutation specifically and dose-
dependently decreases the amount of the aberrantly spliced transcript in favour of the normal 
transcript. However, we could not achieve complete normalization of the splicing pattern 
even at relatively high morpholino concentrations (up to 20 μM). This might be due to 
interference of the antisense oligonucleotide with the assembly of the spliceosome on the 
nearby canonical donor splice site, either by direct steric hindrance or indirectly by masking 
a putative exonic splicing enhancer element which may help define exon 8.     
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In Chapter 6 we designed and tested a morpholino antisense oligonucleotide as well as an 
engineered U7snRNA directed against the F5 IVS8+268A>G mutation, which activates a 
cryptic donor splice site deep in intron 8, causing the retention of an intronic pseudo-exon 
with an in-frame stop codon in the mature mRNA. Also in this case, both antisense 
molecules were able to specifically and dose-dependently restore normal splicing, improving 
the ratio between the normal and aberrant transcript by 1-2 orders of magnitude at the 
highest concentrations used. Remarkably, this was not only observed in a minigene model of 
the patient’s mutation, but also in the patient’s own megakaryocytes differentiated ex vivo 
from circulating hematopoietic progenitors. In fact, treatment with the mutation-specific 
morpholino antisense oligonucleotide or U7snRNA also restored FV protein synthesis in the 
patient’s megakaryocytes, as demonstrated by FV immunofluorescence staining. On the 
other hand, treatment with antisense molecules also produced some cytotoxic effects, which 
however were largely attributable to the transfection agents used for delivery of the antisense 
molecules rather than to the antisense molecules themselves. 
Since in humans both plasma and platelet FV derive from the liver, and since splicing is a 
tissue-specific process, the ideal model to screen antisense molecules for their ability to 
correct a F5 splicing defect would be the patient’s hepatocytes. However, a biopsy of the 
patient’s liver is hardly ever available. Hence the relevance of our megakaryocyte model, 
which makes it possible to test antisense molecules on the patient’s own cells obtained by a 
minimally invasive technique (venipuncture) and to check not only for F5 splicing 
correction, but also for restoration of FV protein synthesis. In the near future this model 
might be replaced by patient’s hepatocytes differentiated ex vivo by induced pluripotent stem 
cell (iPSC) technology.72,73 
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Overall, our findings provide in vitro and ex vivo proof-of-principle for the efficacy of 
antisense-based therapy in at least some forms of FV deficiency. However, before this 
molecular therapy can be applied to FV-deficient patients, several issues will have to be 
addressed, including the choice of antisense molecule (synthetic oligonucleotides vs. 
U7snRNA), its efficient delivery to hepatocytes, the duration of the antisense effect and 
possible side-effects. First of all, a suitable animal model will have to be developed to study 
the bio-distribution and pharmacokinetics, as well as the in vivo efficacy and safety, of the 
antisense molecules and their delivery agents. While transgenic mice expressing the human 
F7 gene in the liver have been successfully used to test a U1snRNA-based splicing 
correction strategy,71 a mouse model would be less suitable for FV deficiency, as FV biology 
is quite different in mice and humans. In particular, platelet FV (the major determinant of 
bleeding tendency in FV-deficient patients) is of megakaryocyte rather than liver origin in 
mice and not strictly required for protection from spontaneous or mild bleeding.74,75 Once the 
efficacy and safety of antisense-based therapy have been established in animal models, 
translation to humans will have to overcome additional difficulties related to the genetic 
heterogeneity of FV-deficient patients (requiring a different and personalized antisense 
molecule, with its own pharmacological and toxicological profile, for each individual case) 
and to the general lack of interest of the pharmaceutical industry for rare (“orphan”) 
diseases. 
 
Role of plasma TFPI in severe FV deficiency 
Previous studies by our group76,77 indicated that the plasma levels of TFPIα and FV are 
highly correlated and that FV-deficient patients have particularly low antigen levels of free 
TFPIα (~35%) and full-length TFPIα (~24%). This was explained with the observation that a 
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large fraction of plasma full-length TFPIα is actually bound to FV, which is likely to protect 
full-length TFPIα from truncation and/or clearance in the circulation.76,78 Recent 
developments have confirmed and extended these findings by showing that FV has a low-
abundance splicing variant, known as FV-short, which binds full-length TFPIα with high 
affinity and stabilizes it in the circulation.79 
In our original study we also proposed that the low full-length TFPIα level would be 
beneficial to FV-deficient patients, as it reduces the FV requirement for minimal thrombin 
generation to <1%.76 Since patients with undetectable plasma FV often have residual platelet 
FV, the low full-length TFPIα levels allow these traces of platelet FV to support minimal 
thrombin generation and to rescue the patients from life-threatening bleeding.80 Based on 
these findings and on the large inter-individual variation of plasma full-length TFPIα 
levels,81 we predicted that plasma full-length TFPIα would be an important modulator of the 
bleeding phenotype in severe FV deficiency.3,76 Unfortunately, however, this hypothesis can 
hardly be tested in epidemiological studies, due to the rare occurrence of the disease and to 
the genetic heterogeneity of FV-deficient patients. 
In Chapter 7 of this thesis we provide evidence for the role of plasma full-length TFPIα as a 
modulator of the clinical severity of FV deficiency. In fact, by comparing two related FV-
deficient patients with equally undetectable plasma FV levels due to the same homozygous 
F5 mutation, but strikingly different bleeding tendencies, we observed that the full-length 
TFPIα level was twice as high in the severe bleeder (proband A, 66%) than in the mild 
bleeder (proband B, 34%). This difference was reflected in their thrombin generation 
capacities and could be largely (though not entirely) abolished by the addition of inhibitory 
anti-TFPI antibodies, suggesting that the elevated full-length TFPIα level was indeed 
responsible for the severe bleeding symptoms of proband A. A parallel difference in plasma 
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full-length TFPI levels was observed between the probands’ fathers, suggesting a genetic 
origin. However, no mutation was identified by direct sequencing of the TFPI gene. 
Therefore, we are now considering the possibility of conducting a whole exome sequencing 
to identify the possible cause of the elevated full-length TFPI level in proband A. 
Full-length TFPIα, which represents only ~10% of all plasma TFPI, is the most biologically 
relevant form of plasma TFPI, because it expresses the highest anticoagulant activity. In 
contrast, the far more abundant truncated forms of TFPIα, lacking the Kunitz-3 domain 
and/or the C-terminus are considerably less potent anticoagulants. Although a genome-wide 
linkage study has provided evidence that a locus on chromosome 2 located close to the TFPI 
gene may influence the level of total TFPI in plasma,82 the major genetic determinants of 
plasma full-length TFPIα are unlikely to reside within the TFPI gene. In fact, the TFPIα 
secreted by endothelial cells undergoes several processes in the circulation, which influence 
its survival in the full-length form. First of all, TFPIα is susceptible to cleavage by numerous 
plasma proteases, including leukocyte-derived proteases (neutrophil elastase, cathepsin G),83 
thrombin,84 FXa,85 FXIa,86 plasmin,87  APC,88 factor VII activating protease (FSAP),89 mast 
cell chymase90 and matrix metalloproteinases.91 Moreover, full-length TFPI has been 
reported to bind to FV76,78 (particularly FV-short),79 protein S92 and high-density lipoproteins 
(HDLs),93 which may protect it from truncation and/or clearance, whereas truncated TFPIα 
binds preferentially to low-density lipoproteins (LDLs).93 In fact, there is growing evidence 
that TFPI physiology is tightly inter-twined with lipid metabolism.94-96 Furthermore, since 
platelets contain 8-10% of all full-length TFPIα present in blood,93,97 platelet activation 
status might also contribute to the plasma full-length TFPIα pool. Based on these 
considerations, the genetic determinants of plasma full-length TFPI level are likely to be 
scattered over several genes belonging to different pathways, including coagulation, 
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fibrinolysis, inflammation, platelet activation and lipid metabolism. Accordingly, a recent 
meta-analysis has reported evidence for the association between plasma full-length TFPIα 
levels and genetic variation in the TFPI, PROS1, F5, APOE and GLA genes,96 while 
genome-wide studies are ongoing in our and other laboratories to identify additional genes 
involved in the regulation of plasma full-length TFPIα levels. The results of these studies 
will help us prioritize the variants identified by whole exome sequencing in the two probands 
investigated in Chapter 7. 
Our finding that plasma full-length TFPIα modulates the bleeding tendency of FV-deficient 
patients also points at plasma TFPI as a possible therapeutic target in severe FV deficiency. 
In particular, TFPI inhibitors may significantly ameliorate the bleeding phenotype of FV-
deficient patients. Since TFPI inhibition has also shown potential as an alternative 
therapeutic strategy for haemophilic patients, several TFPI inhibitors (including non-
anticoagulant sulphated polysaccharides, antibodies, small peptides and aptamers) are 
already available and are currently in various stages of development as potential 
pharmacological agents.98,99 Once approved for haemophilia treatment, these molecules 
might find off-label application in FV deficiency as well. Moreover, a detailed knowledge of 
the determinants of plasma full-length TFPIα levels might suggest novel approaches to 
down-regulate this anticoagulant protein. 
 
Conclusions and future perspectives 
In summary, the work described in this thesis provides new insights into the molecular 
genetics of FV deficiency and paves the way for the development of (personalized) treatment 
strategies. 
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Based on our experience, we propose the following workflow for the identification of the 
genetic defect(s) underlying FV deficiency in patients with a confirmed diagnosis of Owren 
parahemophilia (Figure 1).  
 
F5 gene 
sequencing 
F5 cDNA 
analysis
F5 MLPA 
analysis
Whole 
genome/exome 
sequencing
• Exons
(Chapters 5 & 7)
• Splicing junctions
(Chapter 4)
• Promoter
• 5’-UTR & 3’-UTR
• Missense variants
• Nonsense variants
• Small ins-dels
• Synonymous variants
• Point mutations
• Small ins-dels 
• Point mutations
• Small ins-dels
Effects on protein sequence
Effects on pre-mRNA splicing
Effects on transcription,
mRNA stability and translation
Look for nearby  exonic or deep-intronic mutations potentially 
activating cryptic splice sites or affecting auxiliary splicing signals
• Large deletions 
(Chapter 3)
• Large duplications
Confirm by qPCR / dPCR
Map the breakpoint by long-range PCR 
No mutation or
only one mutation
No splicing defect
No gross gene 
rearrangments
Extragenic mutations potentially affecting FV synthesis, secretion or stability 
• Splicing defects
(Chapters 5 & 6)
 
Figure 1. Proposed workflow for the identification of mutations responsible for FV deficiency. 
First of all, the coding region and all splicing junctions of the F5 gene should be sequenced to 
identify all exonic variants and exonic/intronic variants affecting the donor/acceptor splice sites. 
Ideally this screening should also include the proximal promoter, 5’-UTR and 3’-UTR regions. If no 
mutation or only one mutation is found by this approach, cDNA analysis is recommended to check 
for splicing defects caused by deep-intronic mutations or exonic/intronic mutations affecting 
auxiliary splicing signals. If no splicing defect is detected, an MLPA analysis should be performed to 
look for large deletions/duplications involving multiple F5 gene exons. Finally, if this analysis also 
fails to reveal any abnormality, whole genome/exome sequencing might be warranted to look for 
extragenic mutations potentially affecting FV synthesis, secretion and/or stability in the circulation. 
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As far as treatment is concerned, our work provides in vitro and ex vivo proof-of-principle 
that severe FV deficiency caused by (at least) certain splicing mutations is amenable to 
personalized molecular therapy with antisense oligonucleotides or U7snRNA. The in vivo 
translation of this form of therapy is not yet straightforward, but may take advantage of the 
experience gained with many other genetic diseases. Alternatively, FV-deficient patients 
may benefit from therapeutic approaches based on the inhibition of plasma TFPI, which are 
already under development for the treatment of hemophilia A and B. 
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Summary 
Coagulation factor V (FV) is a large liver-derived glycoprotein present in plasma and 
platelets. After proteolytic activation, it serves as an essential cofactor in the conversion of 
prothrombin to thrombin, accelerating this reaction by several orders of magnitude. This 
function makes FV indispensable to life. FV deficiency is a rare autosomal recessive 
bleeding disorder caused by loss-of-function mutations in the F5 gene. The associated 
bleeding tendency is extremely variable and poorly correlated with plasma FV levels. Since 
FV concentrates or recombinant FV preparations are not available, treatment and 
prophylaxis of FV-deficient patients still relies on fresh frozen plasma, with potential 
complications such as volume overload, allergic reactions and transmission of infectious 
agents. 
The work described in this thesis focusses on the molecular genetics of FV deficiency as a 
starting point for the development of personalized molecular therapies.  
Chapter 1 provides a general overview of the hemostatic system and the coagulation 
cascade, with particular emphasis on the structure, functions and pivotal regulatory role of 
FV. Moreover, it introduces the genetic bases, clinical manifestations and unresolved issues 
of FV deficiency. Since the core of this thesis is dedicated to splicing mutations and their 
correction using antisense-based approaches, Chapter 2 discusses the process of pre-mRNA 
splicing, the various mechanisms by which genetic mutations can alter normal splicing and 
the emerging strategies to correct aberrant splicing using antisense molecules. 
Chapter 3 describes the development and validation of a multiplex ligation-dependent probe 
amplification (MLPA) assay for the efficient detection of large deletions and duplications in 
the F5 gene. Application of this assay to 14 genetically unresolved FV-deficient patients led 
to the identification of a novel ~2-kb deletion spanning intron 8 through intron 10, 
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demonstrating the potential utility of this in-house assay in the molecular diagnosis of FV 
deficiency. 
Chapters 4-6 share F5 pre-mRNA splicing as a common theme. Chapter 4 is a preliminary 
report of a novel F5 splicing mutation affecting the canonical donor splice site of intron 3 
(IVS3+2T>C*), identified in the homozygous state in a toddler with undetectable plasma FV 
levels and multiple intracranial hemorrhages. The mutation introduces a mismatch at the 
invariable +2 position of the donor splice site consensus sequence, most likely leading to 
exon 3 skipping. However, F5 mRNA analysis could not be performed yet. Chapter 5 
presents the genetic and functional characterization of a patient with severe FV deficiency 
and moderate bleeding symptoms. This patient was found to be doubly heterozygous for a 
missense mutation in exon 4 (Cys165Ser) and an apparently synonymous variant in exon 8 
(1371C>G). Analysis of the patient’s cDNA, in combination with a detailed in silico analysis 
and splicing assays in a minigene model, indicated that the latter mutation actually disrupts 
F5 pre-mRNA splicing, activating a cryptic splice site in exon 8 and causing the in-frame 
deletion of 18 nucleotides from the mature mRNA. Additional experiments in the minigene 
model showed that this aberrant splicing event could be corrected in a specific and dose-
dependent manner by a morpholino antisense oligonucleotide designed to mask the incorrect 
splicing signal introduced by the 1371C>G mutation. Chapter 6 extends the application of 
antisense technology to a F5 deep-intronic mutation (IVS8+268A>G) identified in the 
homozygous state in a patient with severe FV deficiency and life-threatening bleeding 
manifestations. This mutation causes the activation of a cryptic donor splice site in intron 8, 
leading to the retention of an intronic pseudo-exon with an in-frame stop codon in the mature 
mRNA. A mutation-specific morpholino antisense oligonucleotide and an engineered U7 
small nuclear RNA (U7snRNA) corrected this splicing defect in a specific and dose-
 
 
 168 
dependent manner, not only in a minigene model of the F5 IVS8+268A>G mutation, but 
also in the patient’s own megakaryocytes obtained by ex vivo differentiation of circulating 
hematopoietic progenitors, effectively restoring FV protein expression in these cells. 
Overall, these data provide proof-of-principle for the efficacy of antisense-based therapeutic 
approaches in severe FV deficiency. 
Chapter 7 reports the case of two distantly related FV-deficient patients who, despite being 
homozygous for the same F5 missense mutation (Trp582Gly) and having equally 
undetectable plasma FV levels, showed very different bleeding tendencies. Phenotyping of 
the patients’ plasma revealed two-fold higher levels of the anticoagulant protein full-length 
tissue factor pathway inhibitor (TFPI) in the severe bleeder (proband A) than in the moderate 
bleeder (proband B). Furthermore, thrombin generation experiments in the absence and 
presence of anti-TFPI antibodies suggested that the difference in plasma TFPI levels may 
indeed account for the difference in bleeding phenotypes. While the cause of the elevated 
TFPI level in proband A is still under investigation, these findings support a physiological 
role for plasma full-length TFPI as a modulator of the bleeding diathesis in severe FV 
deficiency, pointing at TFPI as an additional therapeutic target in these patients.  
Finally, Chapter 8 puts all findings into perspective, discusses them in the light of current 
literature and draws some general conclusions. In particular it proposes an optimized 
workflow for the molecular diagnosis of FV deficiency and it summarizes alternative (and 
personalized) therapeutic options based on the correction of splicing defects using antisense 
technology or on the pharmacological inhibition of TFPI. 
 
__________________________________________________________________________ 
*F5 nucleotides and FV amino acids in this summary are numbered according to the classical 
nomenclature, based on Jenny et al. 1987. 
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Stollingsfactor V (FV) is een groot glycoeiwit dat in de lever wordt aangemaakt en aanwezig 
is in plasma en bloedplaatjes. De geactiveerde vorm van FV dient als een essentiële cofactor 
bij de omzetting van protrombine in trombine, waarbij het de trombinevorming orden van 
grootte versterkt. Hierdoor is FV onmisbaar voor het leven. FV-deficiëntie is een zeldzame 
autosomaal recessieve aandoening veroorzaakt door mutaties in het F5 gen. De hieruit 
volgende bloedingsneiging is variabel en correleert slecht met de FV spiegels in plasma. 
Omdat FV concentraten of recombinante FV producten niet beschikbaar zijn, zijn FV-
deficiënte patiënten nog steeds afhankelijk van vers bevroren plasma voor hun behandeling 
en profylaxe, met potentiële complicaties zoals circulatoire overbelasting, allergische 
reacties en overdracht van infecties. 
Het werk beschreven in dit proefschrift richt zich op de moleculaire genetica van FV 
deficiëntie als uitgangspunt voor de ontwikkeling van gepersonaliseerde behandeling door 
moleculaire therapieën. 
Hoofdstuk 1 geeft een algemeen overzicht van het hemostasesystem en de stollingscascade, 
met bijzondere nadruk op de structuur, functies en centrale regulerende rol van FV. Het 
introduceert de genetische basis, klinische symptomen en onopgeloste vragen van FV 
deficiëntie. Aangezien een groot deel van dit onderzoek gewijd is aan splicing afwijkingen 
en het corrigeren ervan d.m.v. antisense-therapie, beschrijft hoofdstuk 2 het proces van pre-
mRNA splicing, de verschillende mechanismen waarbij mutaties de normale splicing kunnen 
verstoren, en het gebruik van antisense moleculen om afwijkende splicing te corrigeren. 
Hoofdstuk 3 beschrijft de ontwikkeling en validatie van een methode, de zogenaamde 
multiplex ligatie-afhankelijke probe amplificatie (MLPA) test, voor het efficiënt opsporen 
van grote deleties en duplicaties in het F5 gen. Deze assay werd toegepast op 14 genetisch 
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onopgeloste FV-deficiënte patiënten en leidde tot de ontdekking van een nieuwe grote 
deletie die exon 9 en 10 omvat. Deze bevinding bewijst de bruikbaarheid van onze in-huis 
ontwikkelde MLPA test in de moleculaire diagnostiek van FV deficiëntie. 
Hoofdstukken 4-6 hebben als gemeenschappelijk onderwerp de pre-mRNA splicing van het 
F5 gen. Hoofdstuk 4 is een voorlopige beschrijving van een nieuwe homozygote F5 splicing 
mutatie (IVS3 +2T>C*) in een peuter met een niet-detecteerbare plasma FV spiegel en 
meerdere intracraniële bloedingen. Deze mutatie introduceert een mismatch op de 
geconserveerde +2 positie van de donor splice site consensussequentie van intron 3, met 
exon 3 skipping als meest waarschijnlijk gevolg, alhoewel dit niet bewezen kon worden 
omdat de F5 mRNA analyse nog niet kon worden uitgevoerd. Hoofdstuk 5 behandelt de 
genetische en functionele karakterisering van een patiënt met een ernstige FV-deficiëntie en 
een matige bloedingsneiging. Deze patiënt bleek dubbel heterozygoot voor een missense 
mutatie in exon 4 (Cys165Ser) en een schijnbaar synonieme variant in exon 8 (1371C>G). 
Analyse van het cDNA van de patiënt, in combinatie met een gedetailleerde in silico analyse 
en splicing assays in een daartoe opgezet minigenmodel, gaf echter aan dat deze mutatie de 
F5 pre-mRNA splicing verstoort door het activeren van een cryptische splice site in exon 8, 
resulterend in een in-frame deletie van 18 nucleotiden van het mRNA. Additionele 
experimenten in het minigenmodel toonden aan dat deze afwijkende splicing gecorrigeerd 
kon worden door de toepassing van een specifieke morfolino antisense oligonucleotide die 
ontworpen was om de onjuiste splicingsequentie bij de 1371C>G mutatie te verbergen. 
Hoofdstuk 6 breidt de toepassing van antisense-technologie uit tot een F5 “diep-
intronische” mutatie (IVS8+268A>G) opgespoord in een homozygote patiënt met een 
ernstige FV deficiëntie en levensbedreigende bloedingen. Deze mutatie veroorzaakt de 
activering van een cryptische donor splice site in intron 8 die ervoor zorgt dat een 
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intronische pseudo-exon met een in-frame stopcodon in het mRNA blijft zitten. Een mutatie-
specifieke morfolino antisense oligonucleotide en een gemutageniseerde U7 small nuclear 
RNA (U7snRNA) corrigeerden dit splicing defect op een specifieke en dosis-afhankelijke 
wijze, niet alleen in een in vitro minigenmodel van de F5 IVS8+268A>G mutatie, maar ook 
in lichaamseigen megakaryocyten van de patiënt verkregen door ex vivo differentiatie van 
circulerende hematopoietische stamcellen, leidend tot een effectief herstel van de FV eiwit 
expressie. Deze resultaten onderbouwen de effectiviteit van antisense-gebaseerde 
therapeutische benaderingen bij ernstige FV deficiënties. 
In hoofdstuk 7 worden twee gerelateerde FV-deficiënte patiënten gerapporteerd, die allebei 
homozygoot zijn voor de zelfde F5 missense mutatie (Trp582Gly) met bijbehorende 
ondetecteerbare plasma FV spiegels, en toch zeer verschillende bloedingsneigingen 
vertoonen. Fenotypering van het plasma van deze patiënten wees uit dat de ernstige bloeder 
(proband A)  een tweemaal hogere concentratie van het antistollende eiwit full-length tissue 
factor pathway inhibitor (TFPI) in zijn plasma had dan de matige bloeder (proband B). 
Bovendien suggereerden trombinegeneratie experimenten in afwezigheid en aanwezigheid 
van anti-TFPI antilichamen dat het verschil in TFPI plasma concentraties het verschil in 
bloedingsfenotype kon verklaren. Hoewel de oorzaak van het verhoogde TFPI niveau in 
proband A nog onduidelijk is, ondersteunen deze bevindingen een fysiologische rol voor 
full-length TFPI bij het moduleren van bloedingsneigingen bij ernstige FV deficiëntie, 
waarbij TFPI als mogelijk doel voor behandeling aangewezen kan worden. 
In hoofdstuk 8 worden alle bevindingen in perspectief gezet en besproken in het licht van de 
huidige literatuur, resulterend in enkele algemene conclusies en aanbevelingen. Als 
aanbeveling wordt een geoptimaliseerde workflow voor de moleculaire diagnostiek van FV-
deficiëntie voorgesteld. Ten slotte geeft het hoofdstuk een overzicht van alternatieve (en 
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persoonlijke) therapeutische behandelingen op basis van de correctie van splicingdefecten 
met behulp van antisense-technologie of op basis van farmacologische remming van TFPI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*F5 nucleotiden en FV aminozuren in deze samenvatting zijn genummerd volgens de klassieke 
nomenclatuur gebaseerd op Jenny et al. 1987. 
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Science was originally a curiosity-driven activity with no other purpose than to understand 
and explain natural phenomena. Only later it was realized that the knowledge gained by 
exploring nature could be employed to solve practical problems. This dichotomy is still 
reflected in the current distinction between basic and applied research. 
My PhD project was dedicated to the study of the genetics and biochemistry of factor V (FV) 
deficiency, a rare inherited bleeding disorder for which no optimal treatment is available yet. 
Most of the work described in this thesis can be regarded as basic research and was done 
with the primary aim of gaining more insight into the molecular bases of this genetic disease. 
However, some of my results may find practical application in the near or distant future. 
First of all, I have developed and validated a multiplex ligation-dependent probe 
amplification (MLPA) assay for the detection of large deletions and duplications in the F5 
gene. This assay can be performed in any molecular biology laboratory and may be 
implemented immediately in the molecular diagnostics of FV deficiency. The company that 
developed the MLPA technique expressed interest in my assay and invited me for a seminar. 
In addition, I have shown in both in vitro and ex vivo models that some F5 splicing 
mutations responsible for (severe) FV deficiency are amenable to antisense-based RNA 
therapy using antisense oligonucleotides or engineered U7 small nuclear RNA (U7snRNA). 
Although these studies are promising, the in vivo translation of this form of therapy is still 
hampered by the lack of suitable animal models and by the rare occurrence and genetic 
heterogeneity of FV deficiency, each mutation requiring a different custom-made 
oligonucleotide (or U7snRNA) with its own pharmacological/toxicological profile. 
Finally, I have provided additional evidence that the level of plasma full-length tissue factor 
pathway inhibitor (TFPI) is an important determinant of the bleeding tendency in FV-
deficient patients. This finding suggests that TFPI might be a suitable target for 
 
Valorisation 
175 
pharmacological interventions aimed at preventing life-threatening bleeding in severe FV 
deficiency. In this respect, FV-deficient patients may benefit from the TFPI inhibitors that 
are already being developed and tested for the treatment of haemophilia, a much more 
common bleeding disorder. 
Since FV deficiency is a rare disease, with an estimated incidence of 1 in 1 million in the 
general population, it is unfortunately not an attractive target for the pharmaceutical industry. 
This is regrettable, as some FV-deficient patients bleed as much and as severely as 
haemophiliacs, but enjoy a far lower healthcare standard, even in the Western world. Despite 
remarkable advances in transfusion medicine, the repeated administration of fresh frozen 
plasma exposes FV-deficient patients to the risk of transfusion reactions, allergic reactions 
and the transmission of infectious agents, besides taking a toll on the patients’ cardiovascular 
systems on the longer run. On the other hand, the therapeutic development of antisense 
molecules targeting individual mutations for the personalised treatment of a single patient or 
only a few patients is hardly feasible, unless the regulations for clinical testing and licensing 
are specifically modified, as currently being discussed for other rare and/or life-threatening 
genetic diseases with unmet medical needs (Aartsma-Rus et al. Translational and regulatory 
challenges for exon skipping therapies. Hum Gene Ther 2014; 25: 885-892). In this context, 
pharmacological inhibition of TFPI by means of antibodies, peptides, aptamers or small 
molecules could represent a valid therapeutic alternative, suitable for all FV-deficient 
patients irrespective of their mutation(s). 
In conclusion, given the complications associated with the current treatment of FV 
deficiency, it is highly desirable that the long-awaited FV concentrate (currently undergoing 
pre-clinical testing) and/or other forms of therapy, such as those outlined in this thesis, will 
become available soon. 
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